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ABSTRACT
Whitney, Noelle. Health-Related Quality of Life of Children with Duchenne Muscular
Dystrophy. Published Doctor of Philosophy dissertation, University of Northern
Colorado, 2021.
This cross-sectional study examined the influence that age/disease severity, pain, and/or
family functioning have on different domains of health-related quality of life (HRQOL) from the
perspectives of patients with a degenerative neuromuscular disease and their parents. Participants
included 44 parents/caregivers and 39 patients between the ages of 6- and 25-years, who have a
confirmed genetic diagnosis of Becker Muscular Dystrophy (BMD) or Duchene Muscular
Dystrophy (DMD). Patients and/or their caregivers completed measures of HRQOL (PedsQLTM
4.0 Generic Core scales, Varni et al., 1999) and family functioning and well-being (PedsQLTM
2.0 Family Impact Module, Varni et al., 2004), as well as provided general child and family
demographic information. Details regarding patients’ disease status (i.e., usage of steroids and
respiratory-related devices, secondary medical conditions, and comorbid psychiatric and
neurodevelopmental disorders) were also obtained from their medical charts. Univariate analyses
were used to explore characteristics of the sample, disease-specific variables, and all survey data.
Overall, patients and their caregivers reported low levels of physical and psychosocial HRQOL.
Mean scores of caregiver well-being and family functioning were lower for this sample than for
other studies using the same measure with families of pediatric populations. Furthermore, a
series of multivariable regression analyses were conducted to assess associations between
potential correlates and HRQOL scores. Age, family functioning, and/or pain accounted for a
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significant amount of the variance in child-reported and parent-reported Psychosocial Health
Summary scores. The child-reported Physical Health Summary score also demonstrated a
statistically significant model, with age and family functioning having a large influence.
These results suggest that assessing and addressing concerns regarding pain and family
functioning may potentially enhance HRQOL in patients with DMD.
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CHAPTER I
INTRODUCTION
In the United States, a rare disease is defined as a condition that affects less than 200,000
people (U.S. Department of Health and Human Services, 1989). Although any one rare disease is
unlikely to afflict an individual, collectively, 25 to 30 million Americans are diagnosed with one
of the more than 6,500 that exist (Bavisetty et al., 2013; Boat & Field, 2010). These diseases are
often severe and chronic, but far too many are also progressive, debilitating, and ultimately, fatal.
Nearly half of these disorders manifest in childhood (Batshaw et al., 2014; Zurynski et al., 2008),
with most requiring ongoing and complex care due to the lack effective treatment options.
Across these pediatric populations, healthcare has primarily focused on medical outcomes such
as reducing mortality and morbidity and minimizing the number of hospitalizations. Similarly,
medical professionals often arbitrarily used the degree of physical impairment or disease severity
as key indicators of potential psychosocial problems among individuals with chronic health
conditions (Harper & Peterson, 2000), overlooking the importance of formally assessing wellbeing, adjustment to illness, and psychological functioning from the perspectives of patients and
their families.
However, over the last 40 years, developments in research and advancements in medicine
and technology have dramatically changed the clinical course and survival rates of youth with
chronic conditions and rare diseases (Allen et al., 2009; Halfon & Newacheck, 2010; Valdez et

2
al., 2016). In light of these accomplishments, there has been greater emphasis on understanding
youths’ perception of how their illness affects their well-being, daily functioning, and
psychological adjustment. Health-related quality of life (HRQOL) has emerged as a particularly
salient area of interest in clinical practice and pediatric research (Eiser & Jenney, 2007; Varni et
al., 2007). This multidimensional construct examines the impact of an illness, its associated
complications, and treatment regimen on various aspects of an individual’s life (Panepinto,
2008). Within the last decade, there has been an increase in the development and utilization of
pediatric HRQOL measures to improve the health and well-being of children with chronic
diseases and their families (Matza et al., 2004). Along with standard clinical measures and the
expertise of health-care providers, patient-reported outcomes (i.e., assessments of HRQOL) can
provide a more comprehensive evaluation of a child’s functioning across a range of domains
(Bradlyn et al., 2003; Lin et al., 2013), leading to more opportunities for targeted interventions in
areas that are more readily modifiable. Although the number of studies examining HRQOL in
pediatric populations (e.g., epilepsy, cancer, sickle cell disease, and spina bifida) has steadily
grown in recent years, Duchenne muscular dystrophy (DMD), a rare, incurable disease, with a
shortened life expectancy, has received far less attention. Further, the identification of
mechanisms that may explain variations in HRQOL among individuals with DMD may have
significant implications for interventions, health outcomes, and provision of care.
Significance of the Problem
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset
of progressive neuromuscular disorders. DMD is on the severe end of the dystrophinopathy
spectrum and is considered to be the most common and severest pediatric neuromuscular
disorder (Bushby et al., 2010; Darras et al., 2015). Thus, the available research tends to be
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related to DMD and the subsequent information is largely focused on DMD. This disabling
disease is caused by genetic mutations in the DMD gene, leading to insufficient levels of
dystrophin, a protein essential for muscle function (Crean & Tirupathi, 2019; Shenk & RodinoKlapac, 2014). It is transmitted via an X-linked pattern, meaning it almost exclusively affects
males, with an estimated incidence of approximately 1 in every 5,000 births (Mendell et al.,
2012; Moat et al., 2013; Romitti et al., 2015). The hallmark feature of DMD is degenerative
muscle weakness and wasting, which results in multisystem complications and comorbidities
(Morrison, 2011; Pegoraro et al., 2011). Clinical symptoms usually present in early childhood in
the form of gross motor delays (Bushby et al., 1999; Ciafaloni et al., 2009) and eventually
progresses to loss of ambulation during adolescence and limited use of upper limbs at later stages
(Bushby et al., 2010).
The majority of affected boys will struggle with life-threatening respiratory, orthopedic,
and cardiac problems, as well as secondary medical conditions such as pain, sleep problems,
gastrointestinal issues, and swallowing dysfunction (Birnkrant et al., 2018; Eagle et al., 2007;
Mercuri & Muntoni, 2013). Youth with DMD are also at higher risk for neurodevelopmental
disorders (e.g., intellectual disability, autism spectrum disorder, attention-deficit/hyperactivity
disorder) and psychiatric conditions (e.g., obsessive-compulsive disorder, anxiety, and
depression), as well as mild levels of externalizing problems (Banihani et al., 2015; Hendriksen
& Vles, 2008; Pane et al., 2012; Sarrazin et al., 2014; Schmid et al., 2013), all of which may
exacerbate disease severity and affect overall well-being. The profound impairment in muscle
function and multi-organ complications leads to a gradual deterioration in functional abilities,
restricted participation in age-related activities, and increased dependence on caregivers
(Bendixen et al., 2012; Mah et al., 2008; McDonald, 2002).
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As the disease progresses, boys with DMD require consistent utilization of community,
medical, and educational resources and services. The annual direct costs associated with DMD
are approximately seven times higher than the average health expenditures in the United States
(Landfeldt et al., 2016). Equally alarming are the findings regarding the indirect annual costs on
households caring for a boy with DMD (e.g., income loss and monetary value of lost leisure time
and quality of life), which has been estimated between $58,440 and $71,900 (Landfeldt et al.,
2014; Larkindale et al., 2014). Not only do families experience a substantial financial burden, but
also the severity and progressive nature of the disease necessitates routine multidisciplinary care
and adherence to a complex treatment regimen (Birnkrant et al., 2018; Strauss et al., 2015).
While the benefits of the DMD standards of care are well-documented (Ishikawa et al., 2011;
Rall & Grimm, 2012), these therapeutic efforts can also be particularly burdensome, unpleasant,
expensive, and even overwhelming for children and families (Poysky & Kinnett, 2009).
Beyond navigating the complexities of treatment and financial strain of complex medical
care, parents and/or other family members often assume the role of long-term caregiver by
addressing the majority of the medical and non-medical needs of boys with DMD (Boyer et al.,
2006). These responsibilities and potential limitations on employment, personal care, and
involvement in social and leisure activities place caregivers at risk for increased stress, reduced
parental HRQOL, and poorer physical health and psychosocial functioning (Landfeldt et al.,
2014; Magliano et al., 2015; Mah et al., 2008; Nereo, 2003). Similarly, the chronic and
progressive nature of the disease may impair aspects of the family unit including communication,
cohesion, problem-solving, and relationships (Chen & Clark, 2007; Thompson et al., 1998;
Tomiak et al., 2007). Additionally, disruptions in the family’s routine activities and daily
schedule due to disease management or sudden changes in the child’s health status are not
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uncommon. Consistent with the literature on pediatric chronic illnesses (Driscoll et al., 2018;
Herzer et al., 2011; Leeman et al., 2016), reduced family functioning and parental well-being
may subsequently affect health outcomes and HRQOL among individuals with DMD.
Due to improvements in medicine and science, individuals with DMD are now expected
to live into their early 30s (Eagle et al., 2007; Passamano et al., 2012), although this is a
significant medical accomplishment, it has created a growing population with new, under-studied
physical and psychosocial needs, like HRQOL. Given the clinical manifestations of the illness,
the treatment demands, family impact, and the associated functional limitations, it is not
surprising that youth with DMD generally report reduced HRQOL when compared to their
healthy counterparts and youth with other chronic illnesses (Baiardini et al., 2011; Bendixen et
al., 2012; Bray et al., 2011; Henricson et al., 2013; Uzark et al., 2012; Wei et al., 2016). Despite
the important role parents’ play in the lives of their children, especially those with DMD, little is
known about the effects of family functioning and parental well-being on the HRQOL of boys
with DMD. Thus far, extant research has tended to focus on demographic and illness-specific
variables and resulted in mixed evidence regarding the importance of factors such as disease
severity, steroid use, respiratory function, and ambulation status. Elucidating factors that are
potentially and more readily modifiable may prove to be particularly important in informing the
development of interventions that are tailored to the unique needs of the child and their family.
Theoretical Framework
The literature on pediatric chronic illness has established various theoretical models that
guide research and can be used to inform the investigation of HRQOL. Based on the work of
Urie Bronfenbrenner, this theory provides an organizing framework for understanding the
reciprocal interactions between the environment, family, and child, and shapes the experience of
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living with a rare disease, like DMD (Tate & Pledger, 2003). According to the bioecological
theory, the child is embedded within multiple layers of influence: microsystem, mesosystem,
exosystem, and macrosystem, all of which are constantly interacting and influencing each other
(Bronfenbrenner, 1979). The microsystem is the most proximal level and is thought to have the
greatest influence on child development and functioning (Bronfenbrenner & Morris, 1998). It
consists of the child’s immediate surroundings, such as family, friends, teachers, and others who
the child interacts with regularly. Also, the microsystem of a child with DMD extends to include
their symptoms, mental health status, and treatment, exerting influence on both the child and the
family outcomes (Kazak et al., 1995). The mesosystem accounts for the bidirectional interactions
between the structures of the child’s microsystems (Bronfenbrenner, 1986). At this level, the
quality of the family’s relationship and level of communication with the child’s medical team is
critical. The exosystem influences the child indirectly by impacting their immediate
environments. For example, parents have acknowledged that the caregiving demands of children
with DMD can have a significant effect on their social relationships and available financial
resources (Mah et al., 2008), which may heighten parental stress and subsequently affect their
child’s well-being. Similarly, for working parents of children with DMD, workplace policies,
like employee leave time, access to health insurance, and their schedule, can indirectly affect
their child. In this case, a parent may be limited in their ability to leave work without advance
notice when their child with DMD experiences an unexpected change in their health status. The
macrosystem represents the broader cultural context that includes societal norms, values, and
beliefs. For children with a rare genetic disease, like DMD, laws and policies can directly impact
the services that are available or access to care. For example, pediatric research on rare diseases
was largely neglected until the passage of the Orphan Drug Act in 1983 (U.S. Food and Drug
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Administration, 1983), which provided incentives to pharmaceutical companies to develop drugs
and treatments for rare diseases. Lastly, the chronosystem was added to the model more recently,
and it accounts for the influence of environmental changes, transitions, and experiences on
development across the lifespan, including puberty, death, chronic illness, etc. (Bronfenbrenner,
1986). The chronosystem also captures broad societal changes across time and in the case of
DMD, advances in science and the focus on HRQOL and well-being are trends that have
contributed to the functioning of the children with DMD and their families. Overall, this
theoretical framework supports the value and importance of examining factors that extend
beyond the individual to include contextual variables when understanding HRQOL among
individuals with chronic diseases.
Rationale for the Study
Although the life expectancy of individuals living with DMD has increased, there is still
no cure and medical treatments are limited in their ability to mitigate symptoms and associated
complications; thus, HRQOL has been recognized as a priority (Cohen & Biesecker, 2010) that
needs to be considered in the clinical decision-making process. Some researchers even argue that
improving HRQOL is the ultimate goal of healthcare, especially when managing incurable
diseases (Birnkrant et al., 2018; Graf et al., 2006). Despite the growing appreciation of HRQOL
as a valuable outcome measure for children and adolescents with DMD, the body of literature is
still limited, especially when compared to other chronic illnesses. Some researchers have made
efforts to identify factors associated with HRQOL, but most have focused on demographic,
clinical, and disease-specific variables, resulting in mixed findings and limited opportunities to
intervene. Much less attention has been given to understanding the influence of environmental or
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contextual factors, such as caregiver well-being and family functioning, even though the family
plays such a critical role in caring for these children.
Of the available studies examining HRQOL in this pediatric population, several
methodological weaknesses have been identified including the utilization of samples with
various neuromuscular diseases, single informant reports, (i.e., parent proxy only), and
measurement tools with poor psychometric properties. Another common issue across the field is
the variation in the way in which researchers conceptualize the construct of HRQOL.
Specifically, some studies use HRQOL and quality of life interchangeable, but as Wei et al.
(2017) determined, these concepts are related, but distinct.
Purpose of the Study
The current study seeks to address these gaps and weaknesses in the literature by using
information from multiple methods and multiple informants to explore child and family factors
that may contribute to HRQOL in youth with DMD. Such efforts are necessary for identifying
modifiable factors that influence HRQOL, which may serve as potential targets for intervention
and subsequently improve the functioning and well-being of youth with DMD and their families.
Research Questions
Q1

Does age/disease severity, pain, and family functioning
explain child-reported HRQOL scores?

Q2

Does age/disease severity and family functioning
explain parent-reported HRQOL scores?
Delimitations

The most notable delimitation of this study was that a global pandemic occurred at the
outset of data collection, which greatly impacted the achieved sample size and led to changes in
the research protocol. A non-probability convenience sampling method was used to recruit
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participants from a single clinic in the western region of the United States; thus, the results may
not be representative of all boys with DMD and their families. However, it has been argued that
given the severity of the disease, it is reasonable to assume that almost all boys with DMD are
managed at a tertiary-care clinic; thus, patients recruited through such clinics are likely to be
representative of the DMD population. Cognitive and/or other neuropsychological impairments
of some of the participants may have interfered with their ability to complete the measures
and/or impacted the validity of the data obtained from the self-report measures. Lastly, the crosssectional nature of this study limited the casual conclusions that can be made about the results.
Definition of Terms
Cardiomyopathy is a progressive disease that results in aspects of the heart muscle
becoming enlarged, thickened, or stiffened. Overtime, the heart becomes weaker and
ineffective in its ability to pump blood and maintain an adequate electrical rhythm
(McCartan et al., 2012).
Duchenne muscular dystrophy is a neuromuscular disorder that is characterized by
degenerative muscle weakness and wasting, resulting in multisystem complications and
comorbidities, as well as a shortened life expectancy (Morrison, 2011; Pegoraro et al.,
2011).
Dystrophin is a protein that is essential for maintaining the function and structure of
skeletal and cardiac muscle cells. Small amounts of dystrophin have also been found in
the brain and other tissues (e.g., kidneys and retina), but less is known about its role in
these areas (Chelly & Desguerre, 2013; Rando, 2001; Shenk & Rodino-Klapac, 2014).
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset of Xlinked neuromuscular disorders that led to progressive muscle weakness (Crean &
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Tirupathi, 2019; Shenk & Rodino-Klapac, 2014). DMD is at the severe end of the
dystrophinopathy spectrum, while Becker muscular dystrophy (BMD) tends to be less
severe and has a longer life expectancy (Bushby et al., 2010).
Family functioning refers to the “social and structural properties” of the family unit and
larger environment, including the interactions and relationships within the family,
communication patterns, and the roles of the family members (Lewandowski et al., 2010,
p. 2).
Forced vital capacity (FVC) is a measure of pulmonary function that encompasses the
maximum amount of air that can be forcibly exhaled into the hose of
a spirometer (Moore, 2012).
Gowers’ Maneuver is often considered to be an early sign of DMD, in which children use
their hands to push themselves upright when rising from the floor (Emery et al., 2015).
Health-related quality of life is a multidimensional construct examining one’s illness and
associated treatment on their physical, psychological, and social functioning (Panepinto,
2008).
Neuromuscular disorders are a class of inherited and acquired medical conditions, where
the primary pathology is associated with the peripheral nervous system, which includes
the anterior horn cell, the peripheral nerve, the neuromuscular junction, and the muscle
(Dowling et al., 2017).
Parental health-related quality of life encompasses the impact of a pediatric medical
condition on parents functioning and well-being (Varni et al., 2004).
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CHAPTER II
REVIEW OF LITERATURE
This chapter offers a review of the extant literature relevant to the proposed study. The
first section provides a description of DMD including etiology, diagnosis, disease progression,
and associated complications and comorbidities. The second section addresses current methods
of disease management and clinical care guidelines. The third section includes a broad overview
of HRQOL and considerations when measuring this construct. Finally, the chapter concludes
with a discussion regarding known factors associated with HRQOL in children and adolescents
with DMD.
Duchenne Muscular Dystrophy
DMD is recognized as a genetically acquired neuromuscular disorder that is transmitted
via a X-linked recessive inheritance pattern (Dowling et al., 2017). This mode of inheritance
indicates that the disease is the result of a defective gene on the X chromosome. Consequently,
this disease primarily affects males, who receive the mutation on their only copy of the X
chromosome from a “carrier” mother (Khadilkar et al., 2018). Females who receive the faulty
gene on one of their two X chromosomes, rarely develop DMD, and instead are considered
“carriers,” with a 50% chance of passing the mutation to their offspring (Morrison, 2011).
However, carriers have also been known to develop cardiac complications as they age
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(Soltanzadeh et al., 2010; Verhaert et al., 2011). Although the majority of cases are inherited,
there is a high spontaneous mutation rate, with nearly one-third of boys acquiring the disease as a
new random alteration, where there is no known familial history (Bladen et al., 2015).
DMD is caused by a mutation, in one of the largest human genes, the dystrophin gene
(Crean & Tirupathi, 2019; Grigore et al., 2015; Mah, 2016). This gene is responsible for the
production of dystrophin, a protein essential to maintaining muscle function and structure (Shenk
& Rodino-Klapac, 2014). Dystrophin is primarily expressed in skeletal and cardiac muscle cells,
but small amounts have also been found in the brain (Chelly & Desguerre, 2013), as well as
other tissues, including the retina and kidneys (Rando, 2001). Mutations associated with the
DMD phenotype typically result in the absence or a non-functional level of dystrophin in skeletal
and cardiac muscle and other tissues (Aartsma-Rus et al., 2016; Gao & McNally, 2015). In
healthy muscle, dystrophin is part of a large multi-protein complex (i.e., dystrophin-associated
glycoprotein complex [DGC]) that helps to stabilize and protect muscle fibers from damage
during contraction and relaxation (Aartsma-Rus et al., 2016; Lapidos et al., 2004). Thus,
dystrophin deficiency is thought to destabilize the DGC, and in turn, muscle fibers become
susceptible to tearing (Falzarano et al., 2015; Mah, 2016). Over time, the sustained damage
impairs the regenerative capacity of the muscle and allows for an influx of calcium in the cell,
gradually resulting in cell death and the replacement of muscle with fat and scar tissue (Gillis,
1999; Hoffman et al., 1987; Mercuri & Muntoni, 2013). Consequently, muscles do not function
properly and are unable to tolerate the stress of normal contractions, ultimately leading to
progressive muscle wasting.
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Onset and Diagnosis
Newborn screening for DMD is not currently conducted in the United States as part of
the Recommended Uniform Screening Panel (Watson et al., 2006); thus, the disease is rarely
diagnosed during infancy. Skeletal muscles are affected at birth, but most boys do not present
with overt symptoms until early childhood (Darras et al., 2015). Clinical indicators of DMD may
present as early as the first two years of life, in the form of mild delays in gross motor
development (Ciafaloni et al., 2009). Nearly half of all affected boys do not begin walking until
approximately 18 months of age (Emery et al., 2015). Speech and language deficits have also
been noted in 50-70% of children with DMD and may present before concerns of motor
functioning (Ciafaloni et al., 2009). Despite early signs and symptoms, most boys are diagnosed
between 4-5 years-old, when their physical abilities fall behind same-aged peers (Bushby et al.,
1999). Studies have consistently found a delay of two and a half years between the initial
identification of symptoms and a definitive diagnosis (Ciafaloni et al., 2009).
When clinical manifestations of abnormal muscle function are suspected or there is a
family history of DMD, creatine kinase (i.e., an enzyme found in muscle tissues; CK) levels are
often measured (Burtis et al., 2007). Elevations of CK in the blood is indicative of muscle
damage. Regardless of the presence of increased CK levels, genetic testing is necessary to
establish a diagnosis of DMD (Bushby et al., 2010). However, if genetic analyses do not identify
the mutation, a muscle biopsy can be performed to assess for the presence of the dystrophin
protein (Arechavala-Gomeza et al., 2009).
Musculoskeletal
Complications
DMD is characterized by gradual development of muscle weakness and wasting that
progresses from proximal lower limbs to distal upper limbs (Roye et al., 2015). Signs and
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symptoms of the disease are usually observed before age 5, when most boys exhibit gross motor
difficulties including frequent falls and problems running, jumping, and climbing stairs (Parsons
et al., 2004; van Ruiten et al., 2014). Additionally, short stature is often noted, with growth
curves below age expectations during early childhood (Eiholzer et al., 1988). A physical
examination is indicative of abnormal enlargement of the calf muscles by four to five years of
age due to increased muscle bulk, which over time is replaced by fat and scar tissue (Gao &
McNally, 2015). It is not uncommon for families to notice slight gains in their child’s strength
and motor skills between three- and six-years-old, but this is attributed to normal development
outpacing the disease progression (Shenk & Rodino-Klapac, 2014). Unfortunately, these
improvements are short-lived and followed by a gradual deterioration in functioning.
Rigidity in the Achilles tendons forces boys to walk on their toes or the balls of their feet
(Mercuri & Muntoni, 2013). A child with DMD will begin to walk stiffly with a wide-based gait
and his belly pushed out and his shoulders pulled back. Due to weakness in the knees and hips,
Gowers’ Maneuver is also commonly seen, as children use their hands to push themselves
upright when rising from the floor (Emery et al., 2015). These compensatory efforts eventually
become ineffective with the steady deterioration of muscle strength, function, and flexibility in
the hips, thighs, shoulders, and pelvis, and will progress to the point that consistent physical
support and/or the use of assistive devices will be required (D’Angelo et al., 2009).
As the disease progresses, deep tendon reflexes diminish and joint contractures develop,
both of which greatly contributes to the need for leg braces by age 10 and eventually full-time
use of a wheelchair by early adolescence, typically around 13-years-old (Bakker et al., 2002).
However, in recent years, the use of steroids has extended ambulation by two to five years (Eagle
et al., 2002; Moxley et al., 2010). Upper extremity function worsens during the mid-teen years,
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with most boys only able to engage in simple hand movements (Darras et al., 2015). With
declining physical functioning, youth with DMD often find themselves increasingly dependent
on their caregivers to provide assistance with daily living tasks and day-to-day functioning
(Biggar, 2006).
Around the time of the loss of ambulation, the risk of scoliosis (i.e., curvature of the spine)
and/or kyphosis (i.e., hunchback) often increases (Strauss et al., 2015) and further exacerbates
already compromised respiratory and cardiac function. Additionally, DMD is associated with
poor bone health including osteoporosis, which greatly contributes to the high incidence of
fractures within this population (Buckner et al., 2015; Quinlivan et al., 2005). Glucocorticoid
use, weight-bearing exercise restrictions, changes in body fat composition, and immobility have
all been identified as risk factors for reduced bone growth and strength (Joyce et al., 2012).
Respiratory Complications
Progressive deterioration of respiratory function follows a predictable pattern that
coincides with muscle strength, in which initial age-related growth is observed, followed by a
plateau and then a gradual decline, usually during the non-ambulatory stages (Aliverti et al.,
2015; Gayraud et al., 2010). Studies have shown that a global indicator of respiratory function,
forced vital capacity (FVC), is consistently above 70% (i.e., mild level of impairment) in
ambulant boys and generally begins to decrease around age 10, with an average decline of 4-8%
per year (Khirani et al., 2014; Mayer et al., 2015; Phillips et al., 2001). With the loss of
ambulation, FVC usually drops below 50% (i.e., severe pulmonary insufficiency), at which time,
youth begin to experience breathing problems at night that result in morning headaches, sleep
disturbances, daytime fatigue, and loss of appetite (Bushby et al., 2005; Guglieri & Bushby,
2015; Simonds, 2002). Boys with DMD are also at risk for sleep-related breathing disorders
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(e.g., obstructive sleep apnea), secondary to upper airway muscle weakness and weight gain
associated with glucocorticoid therapy (Hoque, 2016). As the disease progresses, FVC will
continue to decline, to the point that difficulties breathing during the day will occur, and survival
beyond 10 months is unlikely without the initiation of ventilatory support (LoMauro et al., 2013;
Toussaint et al., 2007).
Cardiac Complications
With the increase in life expectancy and the advent of ventilatory support, cardiac
dysfunction is beginning to emerge as the leading cause of death in individuals with DMD
(Birnkrant et al., 2015; Kamdar & Garry, 2016; McNally et al., 2015). All individuals with DMD
are at risk of developing cardiac complications, but the course is variable, and studies have not
confirmed reliable markers with prognostic utility (Ashwath et al., 2014). The lack of dystrophin
expression in the heart often manifests as cardiomyopathy, resulting from progressive
replacement of muscle by fibrofatty tissue (Kaspar et al., 2009; Silvestri et al., 2018). Clinical
indicators of cardiomyopathy are usually apparent after age 10, with symptomology steadily
increasing with age, affecting nearly all individuals over 18-years-old (Finsterer & Stöllberger,
2003; Nigro et al., 1990). However, James and colleagues (2011) identified pre-clinical
indicators of cardiac manifestations on electrocardiograms (ECG) in nearly 78% of boys under
age 6, with left ventricle impairment commonly noted. Boys often remain asymptomatic well
into adolescence due to limited physical activity, with the diagnosis of cardiomyopathy often
occurring around 14-years-old (Andrews & Wahl, 2018). Furthermore, as the disease progresses,
abnormalities of cardiac rhythm may also develop including atrial fibrillation, ventricular
tachycardia, and ventricular fibrillation (Birnkrant et al., 2010, 2018; Corrado et al., 2002).
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Neurobehavioral
Complications
Less is known about the function of dystrophin in the brain, but research has established
that DMD is associated with a distinct cognitive and neurobehavioral profile. Although there is
variability in the cognitive functioning of affected youth, full-scale intellectual quotient (FSIQ)
scores of boys with DMD is approximately 1.0-1.5 standard deviations below the mean (Cotton
et al., 2001, 2005; Donders & Taneja, 2009; Hinton et al., 2004; Pane et al., 2012; Snow et al.,
2013; Taylor et al., 2010; Wingeier et al., 2011), with greater impairment in verbal skills than
nonverbal abilities (Bresolin et al., 1994; Cotton et al., 2001, 2005). Specific weaknesses on
subtests measuring short-term memory and expressive language have been identified (D’Angelo
& Bresolin, 2006; Wicksell et al., 2004). Academically, studies have suggested that boys with
DMD are at higher risk for learning disabilities, particularly within the area of reading (Billard et
al., 2008; Hendriksen & Vles, 2006; Hinton et al., 2001, 2004). Youth with DMD have been
found to have lower reading, writing, and math scores on standardized academic tests. Hinton et
al. (2001) reported that the mean standard scores for reading, writing, and math were more than
10 points lower in children with DMD than in the control group, with the most notable issues
observed on the math subtests of the Woodcock-Johnson (WJ) Achievement Battery.
Impairments in executive functioning have also been noted, as children and adolescents with
DMD have been found to have deficits in planning, inhibition, problem-solving, and working
memory (Rae & O’Malley, 2016; Ricotti et al., 2015; Wicksell et al., 2004).
Consistent with deficits in executive functioning, ADHD has been recognized as the most
common neurodevelopmental comorbidity associated with DMD (Hendriksen & Vles, 2008;
Pane et al., 2012). A cohort study of children and adolescents with DMD reported a confirmed

18
diagnosis of ADHD in 33 out of the 103 participants (Pane et al., 2012). Similarly, based on a
standardized parent-reported measure (i.e., Child Behavior Checklist (CBCL); Achenbach,
1991), a high percentage of children between 5- and 16-years-old were rated as above the clinical
threshold for symptoms of inattention (44% of males) and hyperactivity (24% of males) (Ricotti
et al., 2015). Several studies have also highlighted problems with social functioning. For
example, Donders and Taneja (2009) demonstrated that boys with DMD received poorer scores
on the Social Problems and Social Withdrawal scales of the CBCL, while controlling for FSIQ.
When compared to children with cerebral palsy and unaffected siblings, youth with DMD were
rated as having more social behavior problems (Hinton et al., 2006). These findings align with
the emerging body of evidence that has identified higher rates of autism spectrum disorder in this
pediatric population (Hendriksen & Vles, 2008; Wu et al., 2005). Furthermore, children and
adolescents with DMD may exhibit emotional and behavioral difficulties. When compared to the
normative sample, higher rates of internalizing problems were endorsed on the CBCL (i.e.,
Internalizing Problems and Anxious/Depressed Problems) among a sample of 47 Italian boys
with DMD (Colombo et al., 2017). On the other hand, several studies found elevations in both
externalizing (i.e., aggression and hyperactivity) and internalizing (i.e., anxiety and mood
disorders) problems on parent rating scales in this pediatric population (Fee & Hinton, 2011;
Ricotti et al., 2015).
Treatment of Duchenne Muscular Dystrophy
Comprehensive clinical care guidelines developed by the United States Centers for
Disease Control and Prevention (CDC) in collaboration with international and national
organizations, have played a critical role in establishing best practices for the diagnosis,
assessment, and management of DMD (Birnkrant et al., 2018; Bushby et al., 2010). These
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standardized care recommendations emphasize the need for anticipatory and preventive measures
to address primary and secondary symptoms across the disease stages: diagnosis, early
ambulatory, late ambulatory, early non-ambulatory, and late non-ambulatory. A
multidisciplinary approach to disease management has been widely accepted as the ideal method
of treatment, as it allows for the collaborative coordination of care from professionals across a
variety of disciplines (Moxley et al., 2010; Osorio et al., 2018). Not only is a multidisciplinary
service delivery model beneficial to the quality and efficiency of patient care (Otto et al., 2017;
Vry et al., 2016), but it also alleviates some of the indirect consequences of having a complex
condition by limiting travel burden and consolidating visits into a single encounter.
Neuromuscular multidisciplinary clinics are often held at least once every 6 months and
typically operate under the leadership of a medical professional with specialized training in
muscle diseases. The core clinical team is comprised of healthcare providers with a diverse range
of disease-specific knowledge and expertise including but not limited to, cardiology, pulmonary,
rehabilitation, gastroenterology, endocrinology, and psychology (Paganoni et al., 2017). The
contribution of each team member may vary based on the status of individual’s condition across
the lifespan. Although there is currently no treatment that can prevent or reverse the disease
progression, multidisciplinary coordination of care and surgical, pharmacological, and
noninvasive interventions have helped to dramatically increased the life expectancy of
individuals with DMD (Andrews & Wahl, 2018). The following sections outline the most
common treatments across the core disciplines.
Neuromuscular Management
With no cure, glucocorticoids are the most commonly prescribed medications and have
become a standard aspect of care (Henricson et al., 2013). At this time, prednisone (0.76 mg/kg)
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and deflazacort (0.9 mg/kg) are the only medications currently available that have proven to be
effective in delaying the disease progression and preserving functional outcomes (Balaban et al.,
2005; Mah, 2016). Deflazacort recently became the first glucocorticoid for DMD that was
granted full approval by the US Food and Drug Administration (FDA) (U.S. Food and Drug
Administration, 2017). Studies have consistently demonstrated that glucocorticoid therapy
maintains and improves muscle strength and function (Beenakker et al., 2005; Biggar et al.,
2006; Rahman et al., 2001), delays loss of ambulation (Houde et al., 2008; King et al., 2007),
decreases the onset of spinal deformity (Alman et al., 2004; Lebel et al., 2013), and extends
respiratory and cardiac function (Markham et al., 2008). Despite the benefits of glucocorticoids,
there are serious side effects associated with chronic use including behavioral problems,
Cushingoid facial features (i.e., collection of symptoms that evolve from prolonged use of
steroids including a round and puffy face, increased fat around the neck, and acne), loss of bone
mass, growth suppression, and delayed puberty (Guglieri & Bushby, 2015; Houde et al., 2008).
Adverse side effects are frequently cited as the main reason for dosage changes and
discontinuation of these medications (Moxley et al., 2010).
Rehabilitation Management
Prevention of contractures and musculoskeletal deformity requires a combination of
techniques including active and/or active-assisted elongation, passive stretching of muscles and
joints, and limb positioning to minimize flexion with splinting, standing devices, and orthoses
(Skalsky & McDonald, 2012). A stretching program to slow contracture formation should be
implemented early, before the loss of range of motion. Stretching is recommended 4 to 6 times
per week, with greater focus on lower limbs (e.g., ankle, knee, and hip) during the early stage of
the disease and the upper limbs (e.g., wrist, hands, and neck) after the loss of ambulation. To
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preserve muscle strength, children with DMD should also engage in daily aerobic exercise such
as swimming, cycling, and light recreational activities, especially early in the disease (Eagle et
al., 2002).
The use of various orthopedic and assistive devices helps to optimize quality of life and
independence. Specifically, studies have demonstrated the effectiveness of ankle-foot orthoses
(AFOs) in reducing some forms of contractures (de Souza et al., 2016; Hyde et al., 2000).
Standing motorized wheelchairs are now frequently being used to support standing mobility
(Case et al., 2018). There are few assistive devices currently available for upper limb
involvement, but hand splints may help to maintain functional use of hands during the nonambulatory stages (Darras, 2018). Assistive technology and adaptive equipment can also
enhance independence and participation in self-care tasks and leisure activities, as well as
minimize some caregiving responsibilities. Simple adaptations to compensate for upper
extremity weakness include elevated lap trays and/or desks, adaptive straws, plates, and utensils,
and a hands-free water pouch. There is a wide range of technology that may benefit individuals
with DMD such as fall detection systems with Global Positioning System, voice activation and
texting systems on smartphones and tablets, eye gaze equipment for speech, tablet, and computer
accessibility, and smart home systems that are compatible with motorized wheelchairs (Case et
al., 2018). Home renovations may also be necessary to install equipment and modify
environmental barriers (e.g., lifts for transfers, ramps, stair lifts, and special beds) in a way that is
most suitable for the individual and/or the family (Svien & Stuberg, 2001).
Respiratory Management
Progressive weakness in respiratory muscles makes breathing difficult and subsequently
reduces lung volume. Thus, lung volume recruitment devices (e.g., self-inflating manual
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ventilation bag or mechanical insufflation-exsufflation device) are needed to promote greater
expansion of the lungs and chest wall (Chiou et al., 2017; Katz et al., 2015). Additionally, as the
chest wall becomes stiffer, individuals experience difficulties clearing secretions from their
airway (Tzeng & Bach, 2000), at which time, treatment with manual and mechanically assisted
cough devices are beneficial (Bianchi & Baiardi, 2008; LoMauro et al., 2013; Miske et al.,
2004). By the late non-ambulatory stage, assisted ventilation is used to prolong survival (Phillips
et al., 2001). Nocturnal noninvasive intermittent positive pressure ventilation (NIV) should be
initiated when a child’s FVC is less than 50% (Birnkrant et al., 2018; Finder et al., 2004).
Research has shown that NIV is generally well tolerated and it improves symptoms, sleep,
quality of life (Baydur et al., 2000; Eagle et al., 2002), and survival (Passamano et al., 2012; Rall
& Grimm, 2012). With declining pulmonary function, individuals often extend their use of
assisted ventilation into the daytime, which ultimately, progresses to full-time use. Individuals
are typically using most of these treatment options between the age of 18- and 21-years-old
(Stehling et al., 2014). Both permanent NIV and tracheostomy increases the need for extensive
support from caregivers, likely requiring 24-hour care (Gomez-Merino & Bach, 2002).
Cardiac Management
Given the fact that the signs and symptoms of heart failure often go unnoticed in this
population, a proactive approach of early diagnosis and treatment is essential to maximize
survival and quality of life. Baseline evaluation of cardiac function including an ECG or
cardiovascular MRI (CMR) should be conducted at diagnosis or at the latest by age 6, with
annual follow-up until the onset of abnormalities are noted on imaging (Birnkrant et al., 2015,
2018). When symptoms of cardiomyopathy are detected on imaging, pharmacological
intervention should be initiated. In most cases, angiotensin-converting enzyme (ACE) inhibitors
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or angiotensin receptor blockers (ARBs) are used to treat heart disease in patients with DMD
(Allen et al., 2013; Ramaciotti et al., 2006). As the disease progresses, cardiac rhythm
abnormalities may develop, which should promptly be investigated with Holter monitoring, a
portable device that is worn to track heart activity, and treated with standard antiarrhythmic
medications (Birnkrant et al., 2018; Corrado et al., 2002).
Psychosocial Management
Given the improvements in physical health and increased life expectancy of individuals
with DMD, psychosocial functioning has garnered greater attention within the last decade.
Developmental and neuropsychological evaluation can be beneficial in establishing baseline
cognitive functioning and determining the need for community and educational supports. The
Muscular Dystrophy Association has emphasized the value of a variety of classroom
accommodations and adaptive equipment (e.g., a raised desktop or wheelchair tray, physical
assistance for transfers, communication devices, an emergency evacuation plan, access to an
elevator, and use of a note-taker or the ability to record lectures) to help facilitate access to the
educational curriculum and maximize physical abilities (Heller et al., 2008). Although efforts
have been made by local and national organizations to distribute information about the needs of
boys with DMD in educational settings, the literature regarding school functioning and academic
experiences in this population is scarce. A cross-sectional study of caregiver reports of the
educational experiences of 179 school-aged boys with DMD across six states (Arizona,
Colorado, Iowa, Georgia, Hawaii, and New York) was conducted through the Muscular
Dystrophy Surveillance Tracking and Research Network. Results indicated that about a half of
the respondents were receiving occupational and physical therapies, while almost 60% were also
involved in speech language therapy (Soim et al., 2016). Further, 90.5% of the sample were
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participating in a general education setting and more than a quarter of the boys had noted that
they been retained at some point during their schooling. Researchers also examined access to at
least two academic accommodations that tend to be reserved for children with a high level of
special needs. Specifically, approximately 59% of respondents reported that they used a
paraprofessional in general education classrooms and 58% had access to resource room support
with an adapted educational curriculum. The majority of the boys with these accommodations
were identified as non-ambulatory.
Beyond academic needs, the prevalence of neurodevelopmental disorders and psychiatric
conditions among children and adolescents with DMD warrants routine screening and
assessment across the disease stages. Research has also demonstrated that family members are at
increased risk for depression and anxiety (Abi Daoud et al., 2004; Bothwell et al., 2002;
Landfeldt et al., 2016), particularly at major transitions in the disease progression; thus, their
needs and psychological well-being should be evaluated regularly, and intervention or support
offered. Measuring HRQOL has also been identified as a critical method for evaluating the
subjective impact of DMD on the life of the affected child and their family (Guyatt, 1993). When
concerns are identified, the mental health professional on the neuromuscular team should provide
further evaluation and implement evidence-based cognitive or behavioral interventions to treat
the comorbid psychiatric condition(s). Pharmacological interventions may also be necessary for
individuals presenting with psychiatric symptoms.
Given the degenerative nature of the disease and the extensive treatment demands, it is
critical to examine the impact of DMD care and management on HRQOL. There needs to be a
concerted effort to evaluate aspects of functioning beyond just the physical effects of DMD.
Historically, individuals with DMD were not expected to live past their teens, but within the last

25
decade, major milestones in diagnosis and disease management, particularly, the use of
glucocorticoids and standardized care guidelines, have led to a considerable increase in life
expectancy, with most living into their early 30s (Eagle et al., 2007; Passamano et al., 2012).
With no cure, treatment is largely focused on prolonging survival, limiting the degree of
impairment, and enhancing HRQOL (Birnkrant et al., 2018).
Health-Related Quality of Life
HRQOL has evolved from the concept of quality of life (QOL), which is described as a
global dimension of well-being and satisfaction with life circumstances (Edwards et al., 2003).
HRQOL does not typically involve areas associated with the broader aspects of QOL or nonmedical factors, such as cultural, political, or societal characteristics (Ferrans et al., 2005), as
these variables cannot be addressed by medical intervention. Although varying definitions and
conceptualizations of HRQOL exist, there is general consensus that HRQOL is a subjective and
multidimensional measure of well-being that can be affected by illness, injury, and treatment
(Kamphuis et al., 2002; Matza et al., 2004).
There is mounting evidence supporting the utility of measuring HRQOL in pediatric
healthcare, as a means to facilitate patient-provider communication, improve patient/parent
satisfaction with medical care, assess intervention effectiveness, and assist in clinical decisionmaking (Guyatt et al., 1993; Ronen et al., 2011; Varni et al., 2005). Patient-reported outcomes of
HRQOL provide critical information about clinical outcomes and the patient experience with
disease/treatment, all of which may not be readily apparent to the clinician. Thus, along with
standard clinical measures, incorporating HRQOL into medical care can provide a more
comprehensive evaluation of functioning across a broad range of areas (Bradlyn et al., 2003; Lin
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et al., 2013), leading to more opportunities for targeted interventions to improve health and wellbeing (Phipps et al., 2002).
Measurement of Health-Related
Quality of Life
Although there has been an increase in the number of HRQOL scales for use with
pediatric populations (Drotar, 2004), there is variability in the definitions and approaches to
measuring and assessing this construct. HRQOL instruments are commonly categorized as
generic or disease-specific, but there is variability in the approaches to measuring and assessing
pediatric HRQOL. Generic measures usually include an overall or total score across a broad
range of domains including functional status, social functioning, psychosocial functioning, and
family functioning (Andresen & Meyers, 2000). They are designed for use with healthy and
pediatric populations, which allows for comparison of HRQOL scores across groups with
various diseases and/or healthy controls (Solans et al., 2008). Commonly used generic
instruments include the Child Health Questionnaire (CHQ-50; Landgraf et al., 1999), the
Pediatric Quality of Life Questionnaire 4.0 Generic Core (PedsQL 4.0TM; Varni et al., 2001), the
Child Health and Illness Profile (CHIP; Starfield et al., 1995), and the KIDSCREEN (RavensSieberer et al., 2005). However, these tools may lack sufficient sensitivity to detect the impact of
a particular illness (Quittner et al., 2003).
In contrast, disease-specific measures integrate items that are commonly associated with
a certain medical condition (Levi & Drotar, 1999; Quittner et al., 2003). Advantages include the
ability to identify treatment effects and clinically significant changes in a child’s condition or
functioning (Eiser & Morse, 2001; Quittner et al., 2003; Spieth & Harris, 1996). However, they
cannot be utilized for comparative analyses across different disease groups or with the general
population. Several disease-specific instruments are available for children and adolescents with a
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range of medical conditions including neuromuscular disorders (Varni et al., 2004), epilepsy
(Cramer et al., 1999), cystic fibrosis (Modi & Quittner, 2003), and spina bifida (Parkin et al.,
1997).
Historically, HRQOL has been assessed using parent proxy reports, which in recent
years, researchers have begun to recognize the poor concordance between proxy-reports and
child self-reports (Eiser & Morse, 2001). There is now general agreement that self-report is the
“gold standard” for measuring HRQOL; thus, whenever the child is able and willing to complete
self-reported HRQOL measures, it is the ideal option when collecting such data (Matza et al.,
2004; Varni et al., 2007). Regardless, obtaining reports from multiple informants (i.e., child and
proxy reports) is still recommended to gain a more comprehensive perspective of the child’s
HRQOL (Drotar, 2004; Eiser & Morse, 2001). When the child is too young, sick, or cognitively
impaired to provide their own HRQOL, parent proxy measures are recommended (Varni et al.,
1999).
Agreement between self-report and parent-proxy report of HRQOL in boys with DMD is
inconsistent, with some empirical evidence indicating poor to fair concordance rates (Davis et
al., 2010; Uzark et al., 2012; Wei et al., 2015) and others noting moderate to high (Bray et al.,
2010; Landfeldt et al., 2016; Lim et al., 2014). Despite this, the results of these studies revealed
that children with DMD generally rate their HRQOL more favorably than their caregivers. This
discrepancy is usually more pronounced for the psychosocial HRQOL domain. Researchers have
hypothesized that parents’ fears, anticipatory grief, and concerns for their child may
inadvertently affect their assessment of their child’s internal state (Wei et al., 2015). In contrast,
physical HRQOL appears to be more consistent across child and parent-proxy reports, which has
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led some to believe that parents are better at reporting on observable aspects of HRQOL (Bray et
al., 2010; Uzark et al., 2012).
Health-Related Quality of Life of Youth with
Duchenne Muscular Dystrophy
Given the debilitating medical complications of DMD and treatment demands on daily
functioning, assessment of HRQOL is critical and should be part of standards of care for this
population. Literature regarding the HRQOL of children with DMD is somewhat conflicting, but
likely reflective of the heterogeneity in the methodology (i.e., instrument, informant type) and
the varying definitions/constructs of HRQOL. Comparative analyses have demonstrated that
children and adolescents with DMD experience lower overall HRQOL than typically developing
youth, normative samples (Bendixen et al., 2012; Bray et al., 2010; Davis et al., 2010; Henricson
et al., 2013; Lim et al., 2014; McDonald et al., 2010; Uzark et al., 2012), and children with other
chronic illnesses (Bray et al., 2011; Elsenbruch et al., 2013). Across the HRQOL domains (e.g.,
physical, psychological, social, etc.), differences in scores are most consistently observed in the
areas related to physical functioning (Bendixen et al., 2012; Bray et al., 2010; Davis et al., 2010;
Uzark et al., 2012). Analysis of psychosocial HRQOL has resulted in more inconsistencies
across studies. For example, findings have largely revealed that children with DMD receive
lower HRQOL psychosocial scores when compared to controls (Baiardini et al., 2011; Bendixen
et al., 2012; Bray et al., 2011; Davis et al., 2010; McDonald et al., 2010), while others have
found no differences across populations (Opstal et al., 2013; Vuillerot et al., 2010).
Factors Associated with
Health-Related Quality
of Life
In addition to investigating the HRQOL of youth with DMD as compared to unaffected
peers and other pediatric populations, researchers are in the early stages of examining individual,
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disease-specific, and contextual factors associated with lower HRQOL. However, of the
available research, the majority of studies have focused on disease characteristics as correlates of
DMD including disease severity/disability level. Given the degenerative nature of DMD, age is
frequently used as a proxy for disease severity/disability level. Due to the deterioration in
physical functioning and the array of health complications associated with DMD, it is often
assumed that HRQOL worsens with increasing age; however, this has not been clearly confirmed
by the literature. In fact, some researchers have reported deterioration of HRQOL in at least one
domain
In a study of 35 parent-child dyads, younger boys (8 to 12 years) endorsed better physical
HRQOL scores on the PedsQLTM 4.0 Generic Core scale (GCS) than older boys (13 to 17 years),
but no differences were noted on the HRQOL Psychosocial Health Summary score (Bray et al.,
2010). Elsenbruch et al. (2013) also demonstrated that younger boys obtained lower HRQOL
scores on all domains of the DISAKIDS Chronic Generic Module, while a social domain (i.e.,
social inclusion) was the most impacted area for adolescents. Interestingly, work conducted by
Dutch researchers found that children and adolescents with various forms of muscular dystrophy
(i.e., DMD, Becker muscular dystrophy, and limb girdle muscular dystrophy) reported higher
scores on the physical symptoms domain of the TNO-AZL Children’s Quality of Life
Questionnaire (TACQoL), when compared to a normative group (Grootenhuis et al., 2007).
Another study using the same self-report measure revealed that older boys (13-18 years)
endorsed better psychosocial HRQOL than in younger boys (8-12 years) (Uzark et al., 2012).
Likewise, Hendriksen and colleagues (2009) found a similar trend of improved psychosocial
functioning with age. This phenomenon of older children with deteriorating physical abilities
reporting better HRQOL than those with less severe disease symptomology has been coined
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“response shift,” which is thought to occur when the experience of living with an illness leads to
changes in one’s internal standards and self-evaluation (Grootenhuis et al., 2007).
Ambulation status (i.e., ambulatory or non-ambulatory) and ventilation usage (i.e., does
not require ventilation or requires ventilatory support) have also been used as a measure of
disease severity. According to Baiardini et al. (2011), wheelchair use and the need for a
ventilator were found to be associated with parent-reported physical HRQOL scores on the
Children Health Questionnaire-Parent Form 50. Specifically, 27 Italian caregivers rated boys
who were using a wheelchair or ventilatory support as having a lower Physical Summary score
than boys who were still ambulatory. A study by Mah and colleagues (2008) also established that
ventilation usage was associated with HRQOL among Canadian children with Duchenne and
Becker muscular dystrophies, as evidenced by the results revealing that youth who required
ventilation received a significantly lower parent-proxy PedsQLTM 4.0 GCS Total Score than
those not on such treatment. Davis et al. (2010) demonstrated that parent and child ratings on the
PedsQLTM 4.0 GCS and a disease-specific HRQOL measure, the PedsQLTM 3.0 Neuromuscular
Module (NMM), were indicative of reduced scores on the physical domains for those who were
full-time wheelchair users. This finding was not maintained for psychosocial HRQOL scores, as
no differences were found between children who were using a wheelchair and those who were
ambulatory. Similarly, Kohler et al. (2005) used the Short Form-36 to investigate HRQOL in 35
boys with DMD between the ages of 8- and 33- years-old. The researchers concluded that those
who required assisted ventilation did not report significantly lower physical or mental health
scores than those not requiring ventilation. However, the Short Form-36 is designed to assess
HRQOL in adults; thus, it is unknown whether the results provide an accurate assessment of the
pediatric DMD population.
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Given that HRQOL is widely recognized as an outcome measure in healthcare, it is not
surprising that there has been more interest in understanding how changes in clinical measures or
possible functional changes relate to HRQOL. Overall, the physical domains of several HRQOL
measures have been found to correlate with a measure of upper body strength (i.e., physical
therapist-rated Vignos rating scale) (Bray et al., 2010) and timed functional performance
measures (e.g., time to stand from supine, time to climb four stairs) (Elsenbruch et al., 2013;
McDonald et al., 2010; Opstal et al., 2013). Among a small DMD sample (n=35) of boys from
Australia (ages 9-17), child-reported Physical Health Summary Score of the PedsQLTM GCS was
significantly correlated with the Vignos scale (Bray et al. 2010). In contrast, Elsenbruch et al.
(2013) found no relationship between total self-reported HRQOL on the DISAKIDS chronic
generic module and the Vignos scale in a German sample of 50 boys with DMD (ages 8-23).
Researchers have had less success identifying correlations between clinical end points and
psychosocial domains and overall HRQOL scores. However, a recent longitudinal demonstrated
that at baseline the PedsQLTM GCS, PedsQLTM NMM, and the PedsQLTM Multidimensional
Fatigue scale (MFS) were associated with the level of impairment in boys with DMD between
the ages of 5 and 13 years. However, these findings were negligible at the 12-month follow-up.
Beyond physical impairment and motor functioning, Lue et al. (2017) reported that pain
has a significant impact on HRQOL and QOL scores with Taiwanese adolescents and young
adults with DMD. A mixed methods pilot study with 12 young men between the ages of 11 and
21 years-old found that the majority of the participants experienced significant daily pain (twothirds), largely in their legs and back (Hunt et al., 2016). Further, higher parent-reported pain
frequency and severity was significantly correlated with lower self-reported QOL scores on the
Youth Quality of Life Scale (YQOL; Edwards et al., 2003). Parents also acknowledged during an
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interview that pain often or always interfered with their sons’ ability to move, lay down, sit up,
and sleep. Sadly, the assistive devices and medical procedures (e.g., splints, shower chairs, spinal
rods) intended to foster independence and extend ambulation, were often described as
exacerbating their pain. Another concerning finding was that many of these young men rarely
spontaneously communicated when they were experiencing increased pain and discomfort with
their parents, teachers, or medical professionals, despite the fact that they were limited in their
ability to independently manage their pain. Consequently, parents noted that their sons’ pain
often goes unrecognized until overt changes in their behavioral and emotional functioning are
noticed (e.g., crying, emotional outbursts, withdrawn, grumpy). Consistent with these findings,
research with adults living with different muscular dystrophies and other neuromuscular
disorders have indicated that higher rates of pain are associated with lower HRQOL
(Grootenhuis et al., 2007; Jensen et al., 2005; Pangalila et al., 2012).
Contextual Factors
The physical and psychosocial consequences associated with DMD and other chronic
diseases extend beyond the individual, impacting a wide range of personal and family aspects of
life. From a bioecological perspective, a serious stressor, like a chronic childhood disease, plays
a significant role in the family’s social environment and larger context, which reciprocally
impacts the child and their experiences (Bronfenbrenner, 1979). Although the majority of
research on HRQOL in youth with DMD has primarily focused on demographic and clinical
variables, some studies have begun to assess the role of contextual social-environmental factors.
For example, Wei and colleagues (2016) explored child and parent-reported HRQOL in 99
Canadian families of boys with DMD. When compared to a normative sample, child and parentproxy reports on the PEDSQLTM 4.0 GCS were indicative of lower scores across all scales (i.e.,
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physical functioning, emotional functioning, social functioning, and school functioning), with the
largest difference observed on the Physical Health Summary score. The Social Functioning scale
was the only psychosocial domain that fell below the cut-off score, which the authors postulated
was likely related to the physical limitations and/or cognitive deficits commonly seen in this
population.
Due to the exploratory nature of the study, the authors used multiple regression with
backwards elimination to identify a subset of clinical and family variables that were associated
with child self-reported and parent-proxy reported HRQOL across five scores: Pediatric Quality
of Life (PedsQLTM) 4.0 Generic Core total score, PedsQLTM 4.0 Generic Core Physical Summary
score, PedsQLTM Generic Core Psychosocial Summary score, PedsQLTM 3.0 Neuromuscular
Module Total score, and PedsQLTM DMD Module Total score. In terms of sociodemographic
variables, the results revealed that parental education level, annual household income, and family
stress (i.e., Family Inventory of Life Events and Changes (FILE) were the only family
characteristics that correlated with some of the HRQOL scores. This is one of the few studies
that made an effort to investigate family characteristics that impact HRQOL through the use of
both child and parent reports, but these variables were largely limited to demographic
information (e.g., annual household income, marital status, employment status, and educational
level). Although the FILE was included as an index of family stress, it is a unidimensional
instrument that measures general life stressors, not the impact of pediatric chronic conditions on
parent and family functioning.
Another international cross-sectional study by Otto et al. (2017) investigated the
influences of sociodemographic, disease-specific, and social-environmental factors on HRQOL
in boys with DMD and their families across six European countries (i.e., Bulgaria, Denmark,
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Germany, Hungary, Poland, Czech Republic, and United Kingdom). Over 300 participants were
recruited via national DMD patient registries, but the majority of the questionnaires were
completed by parents or caregivers. Several HRQOL measures were used in this study including
the KIDSCREEN-10 index, the Pediatric Quality of Life Inventory (PedsQL), and the
Neuromuscular Module of the PedsQL (NMM). The results revealed that boys with DMD from
households with middle to high income levels endorsed better overall HRQOL scores on the
KIDSCREEN-10 index when compared to boys from low income households. Further, better
HRQOL on the KIDSCREEN-10 index, the PedsQL Total Score, and the PedsQL Psychosocial
Summary Score were reported by boys who spent 6–7 days outside of the home compared to
those who usually spent little time outside the home. Higher HRQOL scores on the
KIDSCREEN-10 index, the PedsQL Total Score, and the PedsQL Psychosocial Summary Score
were also indicative of a better perceived community attitude of boys with DMD compared to
those who felt that community members rarely or never viewed the person with DMD on equal
terms. These results suggest that income, involvement in activities outside the home, and the
perception of the attitudes of the community towards families and their children with DMD may
affect the HRQOL of this pediatric population, which highlights the value of examining the
family context and environmental factors in relation to HRQOL in boys with DMD.
Limitations of Previous Studies
The research on HRQOL among children and adolescents with DMD is still relatively
new, but there are a number of limitations of the existing body of literature that must be
considered. It is important to note that the PEDSQL questionnaires are the only HRQOL
measures that have been specifically validity with this pediatric population (Davis et al., 2010).
Yet, several researchers have opted to use other measures with unknown psychometric properties
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for DMD youth. Furthermore, many of the studies have relied solely on proxy reports, which as
was previously discussed, is problematic because caregivers often underestimate their child’s
HRQOL. Another issue that cannot be overlooked is the use of one method to generate
information on both dependent and independent variables, as it introduces common method
variance due to single source bias (Podsakoff et al., 2003).
Given that DMD is a rare disease, it is not surprising that several researchers have
attempted to increase their sample sizes by including participants with other neuromuscular
diagnoses; however, this makes it challenging to elucidate the HRQOL of boys with DMD.
Recruitment of participants through national registries have also commonly been used in
previous research, which naturally can lead to selection bias, minimize the diversity of the
sample, and reduce the diagnostic uncertainty of the participants. A clinic-based sample may
allow for a more representative sample and the ability to confirm participants’ diagnostic profile.
Although the available studies have provided valuable information, many of the socioenvironmental variables that have been included are generally non-modifiable (i.e.,
demographic) and/or do not capture the larger family context within which children and
adolescents with DMD function. In fact, very few studies have comprehensively assessed the
influence of the family environment and other parent variables on HRQOL in youth with DMD.
There is a need for a more comprehensive examination of HRQOL from both children’s and
parent’s perspectives and exploring factors that are associated with HRQOL.
Summary
The literature has generally established that youth with DMD report reduced HRQOL
when compared to their healthy counterparts and youth with other chronic illnesses. Within
clinical samples of DMD, boys who are considered to be in a more advanced stage of the disease
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tend to endorse lower levels of physical HRQOL. Psychosocial HRQOL across the disease is
more variable, with some studies acknowledging better scores among older children and others
reporting no differences. Similarly, several clinical measures of strength and functioning have
been found to be associated with physical domains of HRQOL, but the same cannot be said for
psychosocial HRQOL. Poor agreement among self- and parent-reports of child and adolescent
HRQOL within this pediatric population have also been noted. Despite the importance of
parents’ in the lives of their children, especially those with DMD, there is little information
known about the effects of family functioning and parental well-being on the HRQOL of boys
with DMD. Thus far, extant research has largely focused on demographic and illness-specific
variables, but elucidating factors that are potentially and more readily modifiable may prove to
be particularly important in informing the development of interventions that are tailored to the
unique needs of the child and their family. Thus, this study seeks to examine how child (i.e., age
and presence of pain) and family variables (i.e., family functioning) impact the HRQOL of boys
with DMD using multiple informants and validated measures.
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CHAPTER III
METHODOLOGY
This chapter outlines the participants, setting, instrumentation, and procedures that were
used in this study to sufficiently answer the research questions. The procedure for recruiting
participants and collecting data is also presented. Lastly, a broad overview of the plan for data
analysis is provided. This study examined the influence of pain, family functioning, and/or
disease severity (i.e., age) on physical and psychosocial HRQOL scores within this medically
complex population.
Participants and Setting
Given that DMD is a rare disease, a nonprobability convenience sampling technique was
used to recruit this targeted population of children and adolescents with dystrophinopathies and
their families. This study was conducted at a multidisciplinary neuromuscular outpatient clinic at
a private, nonprofit hospital located in the western region of the United States. The hospital
serves a seven-state catchment area that covers urban, suburban, and rural populations with
families from a diverse range of races/ethnicities and socioeconomic levels. This clinic is
designated as a Muscular Dystrophy Association (MDA) Care Center, which means it is one of
the less than 200 sites in the United States that offers multidisciplinary care from healthcare
specialists with expertise in neuromuscular disorders. Patients who are followed through the
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clinic are generally seen every six or twelve months by the multidisciplinary team. The team is
comprised of healthcare providers from the following disciplines: neurology, rehabilitation
medicine, pulmonary, physical therapy, respiratory therapy, clinical nutrition, neuropsychology,
social work, and genetic counseling. The contribution of each team member may vary based on
the child’s health status.
Patients were eligible for participation, if they were male between the ages of 5 and 25
with a confirmed genetic diagnosis of a dystrophinopathy and attended their clinic appointment
with a parent or caregiver. Due to the genetic nature of the disease, it is not uncommon for
families to have multiple children with a dystrophinopathy; thus, all children who met eligibility
criteria were asked to participate. Female patients, patients with other neuromuscular disorders,
non-English speaking patients, and those who did not attend clinic with a parent or caregiver
were excluded from this study. Patients who participated in virtual clinic visits were also not
asked to participate.
An a priori power analysis was performed for sample size estimation using G*Power 3.1
(Faul et al., 2009). The alpha utilized for this analysis was .05, as this is the accepted standard in
the behavioral sciences (Cohen et al., 2003). Similarly, as it is the recommended criterion in the
behavioral sciences, power was set at .8 (Cohen, 1988). An effect size of f 2=.35 was chosen for
this study to detect large effects. Thus, with these numbers entered into G*power’s linear
multiple regression: fixed model, R2 increase test, the suggested sample size was calculated at
46. However, due to COVID-19 the sample size was smaller than expected.
Procedures
Institutional Review Board (IRB) approval was obtained concurrently from the
University of Northern Colorado and the Colorado Multiple IRB (Appendix A) prior to

39
conducting data collection. Potential participants were identified from the clinic schedule, and
the clinic coordinator was also consulted to assess families’ eligibility for the study. As children
and their families arrived for their regularly scheduled clinic visit and were placed in a private
exam room, a research team member explained the purpose and nature of the study and the
requirements for participation. The research team members were trained in the process of
informed consent and HIPAA research guidelines, as well as the standards of the sponsoring
IRBs. Participants were informed that consent to participate was completely voluntary and that
they were under no obligation to disclose information or complete any questions that made them
feel uncomfortable. Similarly, it was emphasized that their participation, refusal, or withdrawal
from the study would not influence their current and/or future ability to access medical treatment
with the clinic or hospital. For interested families, parental informed consent (Appendix B)
and/or youth assent (Appendix B) was obtained, prior to the distribution of measures. For
methodological purposes, only one parent’s participation from each household was requested.
Children and their caregivers completed a set of questionnaires in paper form, which
were counterbalanced to control for order effects. Parents and children were instructed to
complete the measures independently. In instances where the research team member and/or
family determined that a patient was unable to complete the questionnaires due to low cognitive
functioning, parents were still offered the opportunity to complete the questionnaires designated
for parent participants. Parents were asked to complete a demographic questionnaire (Appendix
C) and two instruments: The PedsQLTM 4.0 Generic Core scales and the PedsQLTM 2.0 Family
Impact Module. Children completed The PedsQLTM 4.0 Generic Core scales. Medical chart
abstraction occurred within 48 hours of each participants’ clinic visit.
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Due to the sensitive nature of the data collected, specific measures were taken to ensure
that the confidentiality of participants and their families were maintained. Individual names were
not included on any of the questionnaires, instead a unique identifying number was generated for
each participant and their family and was used in place of their names on all data and
questionnaires. To allow for medical chart abstraction, a list linking the participants’ name to
their identifying number was stored in a password protected excel spreadsheet and saved on an
encrypted hospital computer and server. The relevant medical information that was extracted
from participants’ electronic medical charts and the data from the completed questionnaires were
entered into a HIPAA-compliant database, Research Electronic Data Capture (RedCap). The
completed paper questionnaires and informed consents/assents were stored in a locked filing
cabinet. Further, the consent/assent forms were removed from the rest of the raw data and stored
separately to ensure confidentiality of the participants.
It is important to note that shortly after IRB approval, a global pandemic (i.e., COVID19) occurred and the hospital temporarily shut down all non-essential research for several
months. Eventually, hospital research re-entry procedures were implemented, but limitations
were placed on the number of providers and patients that could be present in clinic at one time.
Efforts were also made to decrease the amount of time that patients and their families were
spending in clinic by offering telehealth appointments when feasible and/or eliminating their
visits with providers for non-emergent needs. Consequently, the anticipated sample size was not
achieved, data collection occurred across fewer months, a measure was eliminated, and the
principal investigator was not able to be present in clinic due to COVID-19 protocols at the
hospital.
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Instrumentation
This study used data from a set of demographic questions and two measures that examine
HRQOL and family functioning. Additionally, disease-specific information was extracted from
patients’ medical charts.
Demographic Questionnaire
Parents completed a demographic questionnaire (Appendix C), which was used to gather
information regarding their child’s age, race and ethnicity, primary language, gender, grade
level, age of diagnosis, ambulation status, recent need for emergency services, current
educational supports, and family characteristics (e.g., annual household income, employment
status, parental marital status, living arrangements, parental mental health, primary language
spoken in the home, and parental education level, and maternal disease carrier status).
Disease-Specific Indicators
Electronic medical chart abstractions were conducted to obtain information about disease
characteristics and associated variables for all participants including history of glucocorticoid
use, respiratory status, and the total number of comorbid medical, neurodevelopmental, and
psychiatric diagnoses.
Pediatric Quality of Life Inventory (PedsQLTM)
The PedsQLTM offers a collection of generic and disease-specific instruments that
measure HRQOL in healthy children and adolescents and those with medical conditions. The
PedsQLTM 4.0 Generic Core scales were developed to be used along with the PedsQLTM DiseaseSpecific Modules. Unless otherwise stated below, the information described in this section
applies to all the PedsQLTM instruments that were used in this study. Across the questionnaires,
parallel child and parent-proxy reports are generally available for five age groups: young child
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(5-7 years-old), child (8-12 years-old), teen (13-18 years-old), young adult (18-25 years old), and
adult (ages 26 and older). A 5-point Likert scale is utilized across child self-report for ages 8 to
18 and parent-proxy report, with responses ranging from “Never” (coded 0) to “Almost Always”
(coded 4). Child self-report for ages 5 to 7 uses a 3-point Likert scale with responses ranging
from “Not at all” (coded as 0) to “A lot” (coded 4). Visual anchors are also provided with the
response options for this younger age group. In terms of scoring, items are reverse scored and
linearly transformed to a 0-100 scale (i.e., 0=100, 1=75, 3=25, 4=0), with a higher score
indicating better HRQOL. It is recommended that scale scores are not computed if more than
50% of items in the scale are missing. The PedsQLTM scales are protected by copyright and the
conditions of use for non-funded academic research requires electronic completion of a user
agreement (Appendix D).
Generic Health-Related
Quality of Life
Child self-report and proxy-report versions of the PedsQLTM 4.0 Generic Core scales
were used to measure general HRQOL (Varni et al., 2001). This instrument was developed for
application with both healthy and pediatric patient populations, but it was not intended to provide
detailed information on the specific factors that influence HRQOL in youth with chronic
diseases, like DMD (Iannaccone et al., 2009; Varni et al., 2001). Consistent with the World
Health Organization’s core dimensions of health, this 23-item instrument allows parents and
children to rate their or their child’s functioning during the past month across specific domains:
physical (8 items), emotional (5 items), social (5 items), and school (5 items). It takes
approximately 5 to 10 minutes to complete and provides three overall scores. The Psychosocial
Health Summary Score is obtained by calculating the average of the items across the Emotional,
Social, and School Functioning scales. The Physical Health Summary Score is the average of the
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items on the Physical Functioning scale. The Total Score is obtained by calculating the average
of all the items. Higher scores are indicative of better HRQOL. The Peds-QLTM 4.0 Generic Core
scales have been shown to have adequate internal consistency for the Total Summary Score
(youth self-report: a=.88; parent report: a=.90), Physical Health Summary Score (youth selfreport: a=.80; parent report: a=.88), and Psychosocial Health Summary Score (youth self-report:
a=.83; parent report: a=.86). (Varni et al., 2001). researchers explored cut-off point scores for
designating Psychosocial HRQOL Health Summary scores as impaired among children in the
general pediatric population.
Family Functioning and
Well-Being
The PedsQLTM 2.0 Family Impact Module (FIM; Varni et al., 2004) is a measure of
parents’ perceived HRQOL and the impact of their child’s chronic medical condition on family
functioning during the past month. The FIM includes 36 items across eight dimensions: Physical
Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive
Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items),
and Family Relationships (5 items). The Parent HRQOL Summary Score is obtained by
calculating the average of the items across the Emotional, Social, and Cognitive Functioning
scales. The Family Functioning Summary Score is the average of the items on the Daily
Activities and Family Relationships scales. The Total Score is obtained by calculating the
average of all the items. Higher scores are indicative of better functioning. The initial validation
study reported internal consistency estimates across the FIM scales ranging from .82 to .97
(Varni et al., 2004).
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Research Design
The current study utilized a quantitative and cross-sectional research design with
information from parents, children, and medical records to address the specific research
questions. A cross-sectional design was deemed suitable for this exploratory study that attempted
to identify patterns and relationships between multiple variables (Somekh & Lewin, 2005).
Given that this study was conducted in a hospital setting during patients’ clinic visits, a survey
method and medical chart abstraction was selected due to the minimal time commitment required
for participation and the identification of validated methods of measurement that target the
selected variables.
Data Analysis
All questionnaire and demographic data were analyzed with the IBM Statistical Package
for Social Sciences (SPSS) version 27. Data was checked for completeness prior to entry and
double-checked after entry. The scoring guidelines for each instrument were used to generate
total scores and subscale scores. Univariate analyses were used to explore characteristics of the
sample, disease-specific variables, and all survey data (i.e., mean and standard deviation for
continuous variables and frequencies and percentages for categorical variables). Further, the
reliability of the instruments were examined using Cronbach’s alpha in order to provide
information about the reliability of the investigated measures in the analyzed sample. Pearson
product-moment correlations were used to determine the strength and direction of the
relationships between continuous variables. Point-biserial correlations were conducted between
continuous variables and dichotomous variables. All the demographic data and disease-related
variables were dummy-coded, with the exception of caregiver age. All inferential statistical
analyses were conducted with a significance level of 0.05.
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Simultaneous multiple regression was selected as the main method of data analysis
because it has been identified as a powerful tool when conducting explanatory research to
determine the influence of one or more independent variables on an outcome (Keith, 2006).
Further, this data analysis technique enables the researcher to establish the overall effect of all
the variables and the effect of each variable (Keith, 2006). Given that HRQOL is an emerging
area of interest with pediatric populations, even more so for this rare disease, the literature is still
limited; thus, this study is exploratory. As such, the variables were largely chosen on the basis of
clinical experience, expert opinion, and research with other chronic pediatric diseases.
Prior to examining each of the multiple regression analyses, the necessary assumptions
were tested and are described below in the results section. Four separate regression analyses
were conducted to investigate the influence of age, pain, and/or family functioning on the parentand child-reported scores on the PedsQLTM 4.0 GCS psychosocial domain and the PedsQLTM 4.0
GCS physical domain. All the applicable variables were entered into the models simultaneously.
The F-test was used to assess whether the variables were significantly contributing to the
explanation of the HRQOL scores. Next, R-squared, was assessed to determine how much
variance in the dependent variables, HRQOL scores, were accounted for by the independent
variables. The regression coefficients were used to determine the relative importance of each
variable and the magnitude of their effects. Bonferroni corrections were applied to account for
the multiple regression models.
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CHAPTER IV
RESULTS
Descriptive Statistics
The current sample consisted of 44 parents/caregivers and 39 patients between the ages
of 6- and 25-years old (M=14.02; SD=4.81), who have a confirmed genetic diagnosis of a
dystrophinopathy. Four of the participants had a diagnosis of Becker Muscular Dystrophy
(BMD) and the remainder of the sample had Duchene Muscular Dystrophy (DMD). As
documented in the literature review, children with a diagnosis consistent with Becker tend to
have less severe physical outcomes and a slower disease progression than commonly associated
with DMD. Although the inclusion of these participants in the sample may have skewed the data,
the researcher opted to include these participants in the analyses due to the small sample size and
the lack of research that is available on the psychosocial outcomes of this population.
The sample was comprised of boys who largely identified as White or Caucasian (n=26;
59.1%). Participants’ age at initial diagnosis ranged from 1- to 9-years-old (M=4.86; SD=2.45),
and the time since diagnosis, which was calculated by subtracting their current age from their age
at diagnosis, ranged from 1- to 21-years-old (M=9.20; SD=5.24). Regarding disease-specific
characteristics, the majority of the patients in this study use a wheelchair full-time (n=22; 50%),
regularly take steroids (n=29; 67.4%), and do not currently require any respiratory-related
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devices (n=30; 68.2%). Most of the participants indicated that they have not been seen in an
emergency department (n=40; 90.9%) nor have they been hospitalized (n=41; 93.2%) within the
last 12 months.
The median number of psychiatric and/or neurodevelopmental diagnoses and medical
conditions in the sample was one (SD=1.54; Range=0-6) and four (SD=2.53; Range=0-11),
respectively. Over seventy-five percent (n=34) of the boys had at least one psychiatric condition
or neurodevelopmental disorder. Some of the diagnoses that were listed in patient medical charts
included attention-deficit/hyperactivity disorder (n=12; 27.27%), learning disabilities (n=9;
20.45%), anxiety disorders (n=6; 13.64%), intellectual disability (n=6; 13.64%), autism spectrum
disorder (n=5; 11.36%), speech-language disorders (n=5; 11.36%), and depression (n=3; 6.82%).
Similarly, over 95% (n=42) of patients had been diagnosed with secondary conditions associated
with their dystrophinopathy (e.g., heart-related issues (n=18; 46.15%), obesity (n=19; 48.72%),
scoliosis/spinal curvature (n=15; 38.46%), osteoporosis (n=6; 15.38%), sleep disorders (n=11;
28.21%), and restrictive lung disease (n=23; 58.97%). The grade levels of the boys in this sample
spanned from kindergarten to college, but there were also six older participants who were not
enrolled in any educational programming. Of the participants currently attending elementary and
secondary school, the majority had formal supports and services via an Individualized Education
Program (IEP; n=27; 61.4%) or a Section 504 Plan (n=4; 9.1%), but seven of the boys were not
receiving academic accommodations (15.9%). However, it is important to note that two of these
boys were attending college and could have been receiving accommodations in this setting, but
this information was not obtained.
The parent/caregiver participants primarily indicated that they were their child’s mother
(n=36; 81.8%), while only about 14% of respondents identified as their child’s father (n=6).

48
Caregivers ranged in age from 31- to 69-years-old (M=44.41; SD=8.63) and largely identified as
White, Non-Hispanic (n=28; 63.6%). Most participants noted that they were married (n=33;
75%) and part of a two-parent household (n=36; 81.8%). Half of the sample acknowledged that
they were employed full- (n=26; 59.1%) or part-time (n=11; 25%), meaning that more than 84%
of caregivers were employed. No information was available regarding their partners’
employment status. Most respondents had received some form of post-secondary education
(n=34; 77.2%). In terms of annual household income, approximately 30% (n=13) reported an
income between $75,000 and $99,000. One individual opted to not disclose information
regarding their current income.
Participants were also asked to provide information regarding specific aspects of their
own mental health and genetic testing for disease carrier status. A quarter of caregivers reported
a history of diagnosed mental health problems (n=11). Interestingly, seven of the female
caregivers with a mental health diagnosis had not undergone carrier genetic testing. Given that
DMD is often inherited from a “carrier” mother, the decision to complete genetic testing can be
emotional, with mothers of children with DMD potentially experiencing guilt and self-blame for
learning that they passed the defective gene to their son (Lehmann et al., 2011). However, testing
may also help to alleviate these feelings and provide a sense of control when making decisions
regarding family planning (Colvin et al., 2018). Carrier genetic testing had been completed
within most of the families in this study (n=26; 59.1%), with female caregivers most commonly
having been assessed (n=21; 80.8%). Over 65% (n=17) of those who were tested obtained
positive results for a mutation in the DMD gene. Of the female caregivers who tested positive for
a mutation in the DMD gene, three had a formal mental health diagnosis. Participants’
demographic and clinical information are presented in Table 4.1.
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Table 4.1
Demographic information and clinical characteristics of participants
Category
Patients’ Age

n
39

M (SD)

%

14.02 (4.81)

Race
Asian/Pacific Islander
Hispanic or Latino
More than one race
White, Non-Hispanic

1
13
4
26

Age of Diagnosis
Ambulation Status
Walking
Walking with the use of
Orthotics
Intermittent wheelchair use
Full-time wheelchair use

2.3
29.5
9.1
59.1
4.86 (2.45)

9
1

20.5
2.3

12
22

27.3
50.0

Number of Psychiatric Conditions/
Neurodevelopmental Disorders
0
1-2
3-4
5-6

10
24
7
3

22.7
54.5
15.9
6.8

Number of Medical Conditions
0
1-2
3-4
5-6
7-8
9-11

2
7
14
14
3
4

4.5
15.9
31.8
31.8
6.8
9.2

Kindergarten-5th
6th-8th
9th-12th
College
Not enrolled

12
10
14
2
6

27.3
22.7
31.8
4.5
13.6

Educational Supports
IEP
Section 504 Plan
None
Not enrolled

27
4
7
6

61.4
9.1
15.9
13.6

Caregiver
Mother
Father
Legal Guardian

36
6
2

81.8
13.6
4.5

Grade
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Table 4.1, Continued
Demographic information and clinical characteristics of participants
Category

n

Caregiver Age
Relationship Status
Single
Living with partner
Married

M (SD)

%

44.41 (8.63)
8
3
33

18.2
6.8
75.0

1
4
5
12
3
4
8
7

2.3
9.1
11.4
27.3
6.8
9.1
18.2
15.9

Family Annual Income
$20,000 to $34,999
$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
Over $100,000

6
5
9
13
10

13.6
11.4
20.5
29.5
22.7

Employment Status
Full-time
Part-time
Unemployed
Retired
Homemaker

26
11
2
1
4

59.1
25.0
4.5
2.3
9.1

Household Composition
Two-parent household
One-parent household

36
8

81.8
18.2

Genetic Carrier Testing
Yes
No

26
18

59.1
40.9

Results of Carrier Testing (n=26)
Positive for a DMD mutation
Negative for a DMD mutation

17
9

65.4
34.6

Parental Mental Health Diagnosis
Yes
No

11
33

25.0
75.0

Educational Status
6th-8th grade
9th-12th grade
High school graduate
Some college or certification
Associate degree
Trade/Vocational Training
Bachelor’s degree
Graduate or professional
degree
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Preliminary Analyses
The PedsQLTM 4.0 Generic Core scales and the PedsQLTM 2.0 Family Impact Module
were scored using the instruments’ guidelines and composite and subscale scores were generated
to use as the dependent variables and/or independent variables. All reliability estimates using
Cronbach’s alpha fell above the recommended minimum (≥ .70). The child version of the
PedsQLTM 4.0 Generic Core scales demonstrated good internal consistency for the psychosocial
score (α = .85) and total score (α = .83). The physical score generated the lowest internal
consistency, although it still fell within the acceptable range (α = .78). The parent version of the
PedsQLTM 4.0 Generic Core scales was also indicative of adequate internal consistency across
the physical (α = .82) and psychosocial (α =.89) scales and the total score (α =.87). Regarding
the PedsQLTM 2.0 Family Impact Module, the reliability analyses for the Parent HRQOL
subscale (α = .95) and Family Functioning subscale (α = .93) were excellent. The Total Impact
Score also yielded strong internal consistency (α = .96).
As presented in Table 4.2, correlational analyses were examined to assess the
relationships between HRQOL scores and patient (i.e., age and presence of psychological and
neurodevelopmental conditions) and environmental (i.e., parent HRQOL and family functioning)
variables. Given the smaller than expected sample size, it was important to closely evaluate these
univariate analyses to determine the appropriateness of using all of the potential predictors in the
regression models. Child-reported and parent-reported Psychosocial Summary Scores were
positively correlated with age, suggesting that as patients get older, better psychosocial wellbeing is observed from the perspectives of patients and caregivers. Age was negatively correlated
with the child-reported Physical Health Summary Score. Thus, as patients get older, their
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physical HRQOL score tend to be lower. Interestingly, age was not found to be related to the
Physical Health Summary Score as reported by parents. Family functioning and parent HRQOL
were positively correlated with the child-reported psychosocial and physical scores. Similarly,
parent-reported psychosocial and physical scores were positively associated with family
functioning and parent HRQOL. Thus, better family functioning and parent well-being were
related to higher ratings on the psychosocial and physical domains from the perspectives of both
patients and caregivers. The presence of neurodevelopment disabilities and psychiatric
conditions were not correlated with any of the HRQOL scores. Thus, given the exploratory
nature of the study, the unanticipated smaller sample size, and the lack of associations between
this variable and any of the HRQOL scores, this researcher opted to not include it in any of the
regression analyses. Additionally, due to the strong correlation between parent HRQOL and
family functioning (r=.714, p=.000), as well as the overlapping items between the HRQOL
measure and the FIM, this researcher opted to remove parent HRQOL as a variable in these
analyses to avoid any potential issues with multicollinearity.
Table 4.2
Correlations of Variables
Patient
Psychosocial Physical
Score
Score
.400**
-.324*

Parent
Psychosocial Physical
Score
Score
.392**
-.150

Presence of Neurodevelopmental /
Psychological Conditions

.244

.016

.109

-.048

Family Functioning Score

.312*

.336*

.595**

.353*

Parent HRQOL
.355*
.305*
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).

.527**

.264*

Participants’ Age
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Additionally, efforts were made to examine the relationships between some of the
demographic data, disease-related variables, and the HRQOL scores to determine the need to
enter any of these variables into the regression models. Variables that were significant at a p
value of ≤ 0.005 were included in the appropriate model. All variables were dummy-coded so
that they were dichotomous, with the exception of caregiver age. Relationship status and
household composition were associated with the parent-reported Physical Health Summary
Score, meaning that parents in a relationship/married and caregivers of two-parent households
endorsed higher scores on the physical domain. No associations were identified between annual
income level and the HRQOL scores. Caregiver age was positively correlated with patient- and
parent-reported psychosocial well-being. However, caregiver gender and parental mental health
status (i.e., the presence of a formal diagnosis) were not related to HRQOL domains. Regarding
disease-specific variables, pain was correlated with patient ratings on the psychosocial domain,
indicating that youth reporting lower levels (i.e., “Never” or “Almost Never”) of pain had higher
psychosocial scores. Pain was also significantly correlated with parent-reported psychosocial
scores. In contrast, relationships between steroid usage, sleep problems, and HRQOL scores
were not detected in this study.
Table 4.3
Correlation Matrix of Demographic and Disease-Related Variables
Patient:
Psychosocial
Score

Patient:
Physical Score

Parent:
Psychosocial
Score

Parent:
Physical Score

Relationship Status

-.061

.307

.176

.354*

Annual Income

-.054

-.113

-.097

-.096

Household Composition

.071

-.298

-.193

-.408*

Parental Mental Health Status

-.238

-.098

-.212

-.036

Measures/Demographics
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Table 4.3, Continued
Correlation Matrix of Demographic and Disease-Related Variables
Patient:
Psychosocial
Score

Patient:
Physical Score

Parent:
Psychosocial
Score

Parent:
Physical Score

Caregiver Age

.331*

-.204

.327*

-.003

Caregiver Gender

.089

-.253

.157

-.183

Use of Steroids

-.007

.019

-.075

-.018

---

.356*

---

.124

---

Measures/Demographics

Pain

.443**

Sleep Problems

---

-.104

* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
Participants were asked to complete the PedsQLTM 4.0 Generic Core scales to assess the
HRQOL of this medically complex population from the perspectives of patients and their
caregivers. Completed measures were obtained for 39 children and 44 parents. Five of the
patients did not complete this measure for various reasons. Two of the children were young (ages
6 and 7) and were reportedly unwilling to complete the measure. One of the patients’ parents
were not comfortable with their child completing the measure because they stated that reflecting
on these areas would “make him sad.” The two other participants that did not complete the
measure had a diagnosis of an intellectual disability; thus, the family and/or the research team
determined that the children may struggle to understand the questions.
As shown in Table 4.3, mean scores of parent ratings were slightly lower across all
HRQOL domains when compared to the child’s self-reported scores, with the largest difference
noted for the Psychosocial Summary Scores. Cut-off point scores from a validation study of the
PEDSQL 4.0 Generic Core Scales (Varni et al., 2003) were developed to identify individuals
who were at-risk for impaired HRQOL. Table 4.2 also includes the mean scores and standard
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deviations for children from the validation sample with at least one chronic medical or
psychiatric condition (e.g., ADHD, asthma, diabetes, depression, or “other”). In this study,
nearly 65% (n= 25) of pediatric patients’ overall psychosocial score (i.e., Psychosocial HRQOL
Health Summary Score) fell below the clinical cutoff (<66.03), while over 72% (n=32) of parent
scores were lower than the cut-off (<64.38). According to the cut-off scores for the psychosocial
subscale scores, the most problematic area was the social domain, with nearly 75% (n= 22) of
patients’ and parents’ (n=33) scores below the clinical threshold (<66.61 and <62.07,
respectively). The emotional subscale was the domain that led to the largest discrepancy between
the respondents, as 46% (n=18) of child scores (<59.57) and 61% (n=27) of parent scores
(<63.29) were considered impaired. Although the school subscale score was clinically impaired
(<62.99) for nearly 45% of children, it was the area that the fewest number of participants
identified as an area of concern (n=17). In contrast, 50% (n= 22) of parent scores for the school
domain were impaired (<56.75). Regarding physical functioning, scores were comparable across
both groups, with 100% of patient ratings and over 95% of parent ratings below the clinical
cutoff for physical impairment (<72.98 and <63.28, respectively). Overall, pediatric patients and
their caregivers reported low levels of physical and psychosocial HRQOL. Child scores were
higher than parent ratings of psychological functioning (e.g., emotional, social, and school
functioning), suggesting that children perceive their psychological well-being as being better
than their caregivers’ view of their psychological functioning.
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Table 4.4
The PedsQLTM 4.0 Generic Core scales

Physical
Summary Score
Psychosocial
Summary Score

Child-Report
(n=39)
Mean SD
28.13 17.74

Parent-Report
(n=44)
Mean SD
24.22 18.26

Normative
Sample: Child
Mean
SD
79.46
17.07
(n=574)

Normative Sample:
Parent
Mean
SD
76.99
20.20
(n=830)

61.58

16.43 56.02 17.32

71.32
17.13 71.04
17.32
(n=573)
(n=830)

Emotional
Functioning

61.54

20.06 57.61 19.93

69.32
21.36 71.08
19.75
(n=573)
(n=829)

Social
Functioning

57.69

21.79 50.57 20.72

76.36
21.57 75.06
21.75
(n=572)
(n=824)

School/Work 65.51
Functioning

20.12 59.55 21.18

68.27
19.05 65.58
20.75
(n=568)
(n=756)

13.13 44.96 14.19

74.16
15.38 73.14
16.46
(n=574)
(n=831)

Total Score

49.94

Regarding the PedsQLTM 2.0 Family Impact Module, 44 caregivers completed this
measure to assess parents’ perceived HRQOL and family functioning within the context of a
family with a child with a chronic medical condition. Clinical cutoffs have not been established
for this instrument, but mean scores across most scales were lower for this sample than for other
studies using the same measure with families of pediatric populations. For example, a
preliminary study from Varni and colleagues (2004) found that 11 caregivers with children with
various severe medical conditions (e.g., cerebral palsy and birth defects) obtained a mean Parent
HRQOL Summary Score of 62.94 (standard deviation (SD)=19.83), a Family Functioning Score
of 68.81 (SD=24.11), and a Total Impact Score of 62.49 (SD=7.26). Similarly, 69 families with
children who were post heart-transplant (mean time since transplant was about 4 years) obtained
a Parent HRQOL Summary Score of 72.5 (SD=17.5), a Family Functioning Summary Score of
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75.5 (SD=21.8), and a Total Impact Score of 70.9 (SD=17.1) (Tadros et al., 2020). Given the
terminal and progressive nature of DMD and the associated treatment demands, it is not
surprising that caregivers generally reported lower scores than parents with children with other,
potentially less severe diagnoses.
Table 4.5
The PedsQLTM 2.0 Family Impact Module
Mean

SD

63.55

18.37

Physical Functioning

64.77

17.85

Emotional Functioning

60.68

19.81

Social Functioning

62.07

24.20

Cognitive Functioning

66.14

23.67

Communication

58.52

26.07

Worry

48.86

22.67

Family Functioning Summary Score

57.96

23.87

Daily Activities

51.70

28.11

Family Relationships

61.70

24.49

59.85

18.04

Parent HRQOL Summary Score

Total Impact Score

Regression Analyses
Simultaneous multiple regression was utilized to determine the extent to which age (i.e.,
proxy for disease severity) and specific environmental variables were associated with the
PedsQLTM 4.0 GCS Psychosocial Summary Score and Physical HRQOL Summary Scores as
perceived by patients with dystrophinopathies and their caregivers. Due to the smaller than
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expected sample size with a disproportionately higher number of participants whose ambulation
status was limited, the differences between the Psychosocial Summary Scores and Physical
Summary Scores for both parent and patient ratings were quite pronounced. Deriving an overall
mean functioning score would not have reflected a meaningful representation of the child.
Therefore, the PEDSQL Total Scores were not considered clinically meaningful and ultimately
led this researcher to conduct the analyses with each separate score (Psychosocial Total and
Physical Total). Bonferroni correction was applied because four separate regressions were
conducted. Thus, the significance level of p < .05 was divided by the number of regression
analyses to determine the new significance level of p < .0125. Additionally, due to the
relatedness of the parent HRQOL and family functioning, this researcher opted to eliminate
parent HRQOL as a predictor to avoid the measures confounding the individual effects of each
construct.
Prior to examining each of the multiple regression analyses, the data were evaluated to
ensure that all assumptions were met. The assumption of independence of observations was
checked using the Durbin-Watson statistic, which indicated that the assumption of independent
errors was reasonable across the models with values ranging from 1.73 to 2.02. Values between
1.50 to 2.50 are generally considered acceptable (Keith, 2006). Scatterplots of the residuals and
predicted values confirmed that the relationship between the dependent variables and
independent variables were generally linear. Similarly, a scatterplot of each model was examined
for the spread of the residuals across the predicted values, indicating that the assumption of
homoscedasticity was met. The Variance Inflation Factor (VIF) values ranged from 1.141 to
2.356, which is well below the guideline of 10 (Pituch & Stevens, 2016), confirming that the
assumption of multicollinearity was not violated. The data were examined for outliers by
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reviewing for any studentized residuals greater than ± 3 standard deviations (Laerd Statistics,
2018). Two outliers were identified for the parent-reported Psychosocial Summary Score.
Inspection of these outliers indicated that one of the cases had the lowest parent-reported
psychosocial score (8.33;`x = 56.02), while the other outlier had the lowest scores on the parent
HRQOL (25;`x = 63.55) and family functioning (0;`x = 57.96) domains. The results with and
without the outliers are presented below. The Cook’s distance test confirmed that none of the
cases were placing an undue influence on the models, as none of the data points exceeded 1.00.
Lastly, histograms of the standardized residuals and P-P Plots demonstrated that the psychosocial
models were approximately normally distributed. However, the Physical Health Summary Scores
were indicative of non-normal distributions; thus, a square root transformation was utilized on
the parent- and child-reported physical scores in order to produce more normal distributions.
Following these transformations, the data were re-examined and this researcher again confirmed
that the assumptions were met.
Child-Reported Psychosocial
Health-Related Quality
of Life Model
The results of the first model were significant at the adjusted significance level (F (3, 35)
=6.70, p = .001). The model with all three variables (i.e., age, pain, and family functioning)
accounted for 31% of the total variance of the child-reported Psychosocial Summary score,
which is indicative of a large effect size (f2=.15), according to Cohen (1988). Age (b = 1.16, β =
.334, p = .021) and pain (b = 14.80, β = .398, p = .006) had a significant influence on the model.
Using Keith’s criteria for judging the magnitude of effects, the β associated with age (β = .334)
and pain (β = .398) are considered large (Keith, 2006). Thus, age had a large positive effect on
patients’ ratings on the Psychosocial Health Summary score, suggesting that as patients get
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older, they report higher psychosocial scores. Pain also had a large positive effect on patients’
ratings on the Psychosocial Health Summary score, indicating that youth who indicated that they
experienced pain tended to have a lower HRQOL score.
Table 4.6
Summary of Analysis of Variance for Child-Reported Psychosocial Summary Score
Model
1

Sum of Squares

df

Mean Square

Regression

3742.973

3

1247.658

Residual

6518.173

35

186.234

Total

10261.146

38

F

Sig. (p)

6.699

.001

Notes. Predictors: Age, Pain, and Family Functioning
Table 4.7
Summary of Coefficients for Child-Reported Psychosocial Summary Score
Model Measure
1

B

SE(B)

β

t

Sig. (p)

Age

1.156

.480

.334

2.407

.021

Family Functioning

.120

.096

.174

1.245

.221

Pain

14.798

5.058

.398

2.926

.006

Child-Reported Physical
Health-Related Quality
of Life Model
The results of the second model were significant at the adjusted significance level (F (2,
36) =7.33, p = .002). The model with two variables (i.e., age and family functioning) accounting
for 25.0% of the total variance of the child-reported Physical Summary score, which is indicative
of a medium effect size (f2= .15), according to Cohen (1988). Age (b = -.162, β = -.443, p = .005)
and family functioning (b = .033, β = .440, p = .004) had a significant influence on the model.
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Using Keith’s criteria for judging the magnitude of effects, the β associated with age (β = -.443)
and family functioning (β = .440) are considered large (Keith, 2006). Thus, age had a large
negative effect on patients’ ratings on the Physical Health Summary score, suggesting that as
patients get older, they report lower physical scores. Family functioning also had a large positive
effect on patients’ ratings on the Physical Health Summary score, indicating that patients from
families who endorse better family functioning reported higher physical scores.
Table 4.8
Summary of Analysis of Variance for Child-Reported Physical Summary Score
Model
1

Sum of Squares

df

Mean Square

Regression

34.918

2

17.459

Residual

85.666

36

2.380

Total

120.584

38

F

Sig. (p)

7.337

.002

Notes. Predictors: Age and Family Functioning
Table 4.9
Summary of Coefficients for Child-Reported Physical Summary Score
Model
1

Measure

B

SE(B)

β

t

Sig. (p)

Age

-.162

.054

-.443

-2.992

.005

Family Functioning

.033

.011

.440

3.042

.004

Parent-Reported Psychosocial
Health-Related Quality
of Life Model
The results of the overall model for the third multiple linear regression model were
statistically significant at the adjusted significance level, (F (2, 41) =14.49, p =.000). The model
with both variables accounted for 38.6% of the total variance of the parent-reported Psychosocial
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Health Summary score, which is indicative of a large effect size (f2=.35), according to Cohen
(1988). Age (b = .915, β = .254, p = .047) and family functioning (b = .384, β = .529, p = .000)
had an explanatory effect on the model. Using Keith’s criteria for judging the magnitude of
effects, the β associated with age (β = .254) and family functioning (β = .529) are considered
large (Keith, 2006). Thus, age had a large positive effect on patients’ ratings on the Psychosocial
Health Summary score, suggesting that as patients get older, their caregivers report better
psychosocial functioning. Family functioning also had a large positive effect on parents’ ratings
on the Psychosocial Health Summary score, indicating that parents who endorsed better family
functioning perceived their child’s psychosocial HRQOL to be higher.
As noted above, two outliers were identified in this model, without these outliers (n=42),
the overall model remained statistically significant (F (2, 39) =24.13, p =.000) and accounted for
55.3% of the total variance of the parent-reported Psychosocial Health Summary Score, with
both variables having an explanatory influence on the model (age: b = .819, β = .240, p = .034;
family functioning: b = .467, β = .659, p = .000). However, given the smaller than expected
sample size and the unique contribution of these participants to the diversity of this sample, this
researcher opted to retain the outliers.
Table 4.10
Summary of Analysis of Variance for Parent-Reported Psychosocial Summary Score
Model
1

Sum of Squares

df

Mean Square

Regression

5343.040

2

2671.520

Residual

7557.503

41

184.329

Total

12900.542

43

Notes. Predictors: Age and Family Functioning

F
14.493

Sig. (p)
.000
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Table 4.11
Summary of Coefficients for Parent-Reported Psychosocial Summary Score
Model
1

Measure

B

SE(B)

β

t

Age
Family Functioning

Sig. (p)

.915

.446

.254

2.051

.047

.384

.090

.529

4.268

.000

Parent-Reported Physical
Health-Related Quality
of Life Model
The final multiple linear regression model was not significant at the adjusted significance
level of p < .0125. Age and family functioning did not predict the parent ratings on the Physical
Summary score (F (2,41) = 4.74, p = .014); R2=.148), although the model would have been
significant without the Bonferroni correction for multiple tests.
Table 4.12
Summary of Analysis of Variance for Parent-Reported Physical Summary Score
Model
1

Sum of Squares

df

Mean Square

Regression

39.222

2

19.611

Residual

169.692

41

4.139

Total

208.913

43

Notes. Predictors: Age and Family Functioning

F
4.738

Sig. (p)
.014
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Table 4.13
Summary of Coefficients for Parent-Reported Physical Summary Score
Model
1

Measure

B

SE(B)

β

t

Age
Family Functioning

Sig. (p)

-.119

.067

-.261

-1.787

.081

.039

.013

.421

2.887

.006

Conclusion
Overall, this exploratory analysis led to several key findings. Patient and caregiver
ratings on the Psychosocial and Physical Health Summary Scales fell below the clinical cutoffs,
with the social domain identified as the most problematic area across both respondent groups.
Mean scores across scales of a measure of caregiver well-being and family functioning (i.e.,
PedsQLTM 2.0 Family Impact Module) were lower for this sample than for other studies using
the same measure with families of pediatric populations. Several demographic variables were
correlated with the HRQOL scores (i.e., relationship status, household composition, and
caregiver age). Similarly, a disease-specific factor, pain was indicative of a strong correlation
with patient ratings on the psychosocial domain. Thus, the strong correlation that was identified
for pain and child-reported psychosocial HRQOL, warranted inclusion in the regression model.
A series of multivariable regression analyses were conducted to assess associations
between potential correlates and HRQOL scores from the perspectives of patients and their
caregivers. Age, family functioning, and/or pain accounted for a significant amount of the
variance in child-reported and parent-reported Psychosocial Health Summary scores. The childreported Physical Health Summary score also demonstrated a statistically significant model, with
age and family functioning having the largest influence on this domain. In contrast, the model for
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parent-reported Physical Health Summary Score was approaching significance with age and
family functioning but did not meet the level defined by the Bonferroni correction.
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CHAPTER V
DISCUSSION
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are a subset
of X-linked neuromuscular disorders that are characterized by degenerative muscle weakness and
wasting and multisystem complications that impact physical, cognitive, social, and psychological
functioning (Birnkrant et al., 2018; Darras et al., 2015; Morrison, 2011). Youth with
dystrophinopathies are also at a higher risk for neurodevelopmental disorders and psychiatric
conditions (Banihani et al., 2015; Conway et al., 2016; Sarrazin et al., 2014), all of which likely
further exacerbates disease severity and affects overall well-being. The profound impairment in
physical function and complex treatment regimen leads to increased dependence on caregivers
(Bendixen et al., 2012), especially after loss of ambulation. Research has demonstrated that youth
with DMD present with reduced HRQOL, but much less is known about predictors of this
multidimensional construct. The aim of this exploratory study was to assess disease severity via
age and potential modifiable psychosocial factors of HRQOL from the perspective of pediatric
patient self-report and parent proxy-report.
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Overview of the Results
As measured by the PedsQLTM 4.0 Generic Core scales, patient and parent ratings across
all domains of HRQOL (i.e., physical, emotional, social, and school) were below proposed cutoff scores, with the physical subscale rated as the most problematic area across both respondent
groups. Given that the hallmark feature of this disease is progressive muscle wasting, it is not
surprising that physical HRQOL emerged as the lowest mean score within this sample, especially
since it was comprised of more boys whose ambulation status required part-time or full-time
wheelchair use. An item-level examination indicated that over 25% of patients endorsed
experiencing pain/aches “often” or “almost always” within the last month of completing this
measure. Almost 40% of parents felt that pain was an area of concern for their children. Within
the psychosocial domain, the social subscale was the area that was most impacted as reported by
both parents and patients. It is likely that diminished social HRQOL in this pediatric population
is related to a combination of factors including cognitive deficits, physical limitations and
secondary symptoms of pain and fatigue, and feelings of self-consciousness with changes in
functioning. Consequently, children with DMD may be less inclined to seek out peer
relationships and social activities. Research has also shown that youth with DMD are at higher
risk for social skills deficits (Hinton et al., 2006). In fact, this sample was comprised of patients
with formal diagnoses (i.e., ADHD, autism spectrum disorder, and speech-language disorders)
that have been found to be associated with weaknesses in social functioning. Overall, the trend in
scores in this study aligns with other research using this measure with boys with
dystrophinopathies (Baiardini et al., 2011; Bendixen et al., 2012; Bray et al., 2011; Davis et al.,
2010; Elsenbruch et al., 2013; Uzark et al., 2012).
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Given the progressive nature of DMD and the increased reliance on caregivers for
support, disease management, and daily functioning, it is not surprising, that the mean scores on
the PedsQLTM 2.0 Family Impact Module were lower in this study than for other pediatric
samples using the same measure (Tadros et al., 2020; Varni et al., 2004). It is important to note
that the diagnoses of the samples in these studies are not considered to be as severe as a
condition like DMD, a progressive, life-limiting, and ultimately, terminal disease. Furthermore,
the subscale that was identified by caregivers as being most impacted in this sample was the
worry subscale, with the majority of respondents acknowledging that they experience worries
“often” or “almost always” in one or more of the following areas: their child’s future, medical
treatments, side effects, others’ reactions to their child, and/or the impact of the illness on other
family members. This finding is consistent with other prior work demonstrating that the worry
subscale emerged as the lowest outcome on this measure (Jastrowski Mano et al., 2011; Tadros
et al., 2020).
Although not a formal research question, correlational analyses were conducted between
demographic variables and disease-specific factors and the HRQOL scores. Pain was indicative
of strong correlations with patient ratings on the psychosocial domain. Research has
demonstrated that these secondary symptoms of DMD have emerged as correlates of HRQOL
(Hunt et al., 2016; Ozyurt et al., 2015). Several demographic variables (i.e., family composition,
relationship status, and caregiver age) were found to be correlated with the HRQOL scores,
which aligns with the existing research that has shown mixed evidence for the significance of
such factors on HRQOL. For example, a longitudinal, multi-site international study with children
with DMD and their families found that boys with DMD living in a household with a medium to
high income level reported better HRQOL on the KIDSCREEN-10 index when compared to
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those living in a low income household (Otto et al., 2017). In contrast, other studies have found
no associations between income level and HRQOL scores (Wei et al., 2016). In this study, the
sample does not reflect the diverse population in terms of race, disease stage, parental marital
status, income level, and family composition. Thus, it is possible that the limited diversity in this
sample contributed to the largely non-significant socio-demographic findings.
The first set of research questions aimed to determine which modifiable psychosocial
variables contributed to the child-reported HRQOL scores. For the psychosocial HRQOL score,
30% of the variance was explained by age, pain, and family functioning, but age and pain were
the only variables that had a significant influence on the model. This study demonstrated that
patients who indicated that they experienced pain/aches “never” or “almost never” had higher
psychosocial HRQOL scores. Pain has been reported to be associated with reduced HRQOL in
various pediatric populations (Gold et al., 2009; Jones et al., 2015; Sawyer et al., 2005). Yet,
there is limited research on the pain experiences of youth with DMD. The few studies that have
examined pain in children with DMD have used different measures to assess for pain or
HRQOL, making it difficult to make direct comparisons to these studies. For example, a pilot
study by Hunt et al. (2016) found that parent’s ratings of pain frequency and severity correlated
with lower patient-reported HRQOL scores on the Youth Quality of Life Scale among 12
Taiwanese men with DMD.
Furthermore, age emerged as a predictor that had a large effect on patients’ ratings on the
Psychosocial Health Summary score, suggesting that as patients get older, they report higher
psychosocial scores. Although age and other proxies of disease severity (e.g., ventilator use)
have resulted in mixed evidence (Hendriksen et al., 2009; Otto et al., 2017; Uzark et al., 2012),
this finding is consistent with research supporting the phenomenon known as “response shift,” in
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which better psychosocial HRQOL outcomes found in older youth with more severe disease
symptomology may be related to changes in values, priorities, internal standards, or
conceptualization of well-being, as they adapt to their diagnosis (Sprangers & Schwartz, 1999;
Szabo et al., 2020).
For the physical HRQOL score, 25% of the variance was explained by age and family
functioning, with both variables contributing to the model. This suggests that patients rated their
physical HRQOL higher when their caregivers endorsed better family functioning. This is the
first study to examine the predictive influence of family functioning (i.e., PedsQLTM 2.0 Family
Impact Module) on HRQOL within this pediatric population using a multidimensional measure
for families with children with medical complexities. Prior work in the broader pediatric
literature demonstrates that indicators of general family functioning (i.e., family cohesion,
communication, problem-solving, distress level) are related to better HRQOL (Cipolletta et al.,
2015; Fee & Hinton, 2011; Herzer et al., 2011; Moreira et al., 2013; Quast et al., 2018).
However, given that these studies used more general measures of family functioning, it is likely
that they do not take into account the disease experience (e.g., treatment demands, caregiving
burden), which is the likely culprit that is greatly contributing to their stress and dysfunction.
Furthermore, age had a large negative effect on patients’ ratings on the Physical Health
Summary score, suggesting that as patients get older, they report lower physical scores. Existing
research with youth with DMD has demonstrated that increasing age has generally been
associated with poorer self-reported physical HRQOL (McDonald et al., 2010; Uzark et al.,
2012). Given that the disease progression of DMD leads to worsening physical limitations over
time, it makes sense that older boys within this sample endorsed poorer physical well-being.
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The final set of research questions aimed to determine which modifiable psychosocial
variables contributed to the parent-reported HRQOL scores. For the psychosocial HRQOL score,
39% of the variance was explained by age and family functioning, with all the variables having a
significant influence on the model. This suggests that caregivers rated their child’s psychosocial
HRQOL higher when they endorsed better family functioning. As mentioned above, family
functioning has not been evaluated as a predictor of HRQOL in DMD. Existing research has
largely been restricted to general family functioning or parenting stress measures, which likely
do not include stressors and experiences commonly experienced in families with a child with a
complex medical condition. Consistent with the patient-reported outcomes, age also
demonstrated a large negative effect on their child’s psychosocial HRQOL in DMD. For the
physical score, the model was not significant at the adjusted significance level of p < .0125,
which is likely due to the small sample size. Given the moderate correlations that were identified
between some of the demographic variables (i.e., caregiver relationship status and household
composition) and the parent-reported physical HRQOL score, it is also possible that these
demographic variables may serve as more relevant predictors of this outcome.
Implications
Historically, individuals with DMD were not expected to live past their teens, but
improvements in medicine and science, have led to a considerable increase in life expectancy,
with many living into early adulthood (Eagle et al., 2007; Passamano et al., 2012). Although this
is a significant medical accomplishment, there is still no cure and medical treatments are limited
in their ability to mitigate symptoms and associated complications; thus, as patients have begun
to live longer, psychosocial care has increasingly become a priority (Cohen & Biesecker, 2010).
In fact, in recent years, standardized care guidelines for DMD have recommended the need to
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focus on prevention and interventions efforts to address well-being in patients and their families
across the disease stages. Pediatric psychologists and mental health providers have been
recognized as integral to the multidisciplinary medical team for youth with DMD, particularly as
it relates to screening, monitoring, and implementing therapeutic interventions for patients and
their families, as well as involvement in care coordination (Birnkrant et al., 2018; Bushby et al.,
2010).
HRQOL, a potentially modifiable outcome, has been recognized as a multidimensional
construct that can be used to inform both medical and mental health treatment with pediatric
populations. Much of the existing research has examined HRQOL from the perspective of the
parent only, but this study examined HRQOL via both caregiver report and child self-report,
which offers a more comprehensive overview of HRQOL in this medically complex population.
Historically, HRQOL has been assessed using parent proxy reports, but there is growing
consensus that self-report is critical for measuring HRQOL (Matza et al., 2004; Varni et al.,
2007), especially as research has demonstrated poor agreement between parent and child ratings
(Bray et al., 2010; Eiser & Morse, 2001). Mean scores of parent ratings were slightly lower
across all HRQOL domains when compared to the child’s self-reported scores. The most
pronounced differences emerged on the psychosocial subscales, with parents perceiving their
children as presenting with more social, emotional, and school difficulties than their children.
Although only slight discrepancies between youth and caregiver reports were identified in this
study, discordance has consistently been observed in the literature. Unless clinically warranted
(i.e., cognitive deficits), efforts should be made to obtain data from multiple sources when
assessing HRQOL. Relying on a single source for examining HRQOL may also impact referrals
for services and participation in interventions (Goldstein-Leever et al., 2019).
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Consistent efforts to engage in screening and monitoring of HRQOL in youth with DMD
can aid in identifying children who are at risk for impaired well-being and guide decision making
related to treatment and intervention. Results of this study suggest that boys with
dystrophinopathies present with low levels of physical and psychosocial health-related quality of
life from the perspectives of both parents and patients. Given the clinical manifestations of
DMD, it is not surprising that parent and child ratings of physical HRQOL were severely
compromised. Thus, clinicians should ensure that efforts are made to help support patients and
their families in identifying equipment, assistive technology, and other resources to facilitate
accessibility and independence, all of which may also ease caregiver burden. Assisting families
in connecting with community-based waiver programs and financial resources for modifications
to their homes would also likely be valuable.
Beyond physical functioning, psychosocial scores fell below the clinical cut-offs for the
majority of the sample as reported by both children and parents. The social domain of HRQOL
was identified as the most problematic area across respondents. As physical impairment worsens
and secondary symptoms of pain, fatigue, and sleep problems become more pronounced, youth
may begin to experience increased feelings of self-consciousness and be less inclined to seek out
peer relationships and social activities. Given that schools are a main source of socialization for
children, collaboration with school professionals is an ideal way to support this area of need. In
my professional experiences, patients have found therapeutic benefits in formally sharing their
experiences living with a medically complex disease with their teachers and classmates, which
may also help to foster disability awareness and a more inclusive environment of social
acceptance. Similarly, supporting patients in creating scripted answers to commonly asked
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questions from peers and/or helping them to develop a simple description of their medical
condition has anecdotally helped youth with DMD feel more at ease in social situations.
Educational teams are well-positioned to be able to facilitate accessible extracurricular
activities and individualized supports in the school setting that enhance interpersonal
relationships, while also limiting the burden on families of pursuing these resources and/or
activities in alternate environments. For example, an Australian school-based group intervention
study (i.e., MD Mafia) for boys with muscular dystrophies identified several positive qualitative
themes from participants and their parents after their involvement in this unique experience
including increased opportunities for belongingness, accessible social interactions independent of
their families, and improvements in self-confidence (Parkyn & Coveney, 2013). Although
limitations in physical functioning may interfere with youths’ level of social engagement,
research has also shown that patients with DMD are at higher risk for social skills deficits
(Hinton et al., 2006). This sample was comprised of patients with formal diagnoses of ADHD
(27%), autism spectrum disorder (12%), and speech-language disorders (11%), all of which are
neurodevelopmental conditions that are commonly associated with weaknesses in social
functioning. Thus, social skills training may be a suitable option to consider for youth with DMD
and comorbid psychiatric and neurodevelopmental diagnoses to address a potential skill deficit
and increase peer connections.
Thankfully, the majority of the school-aged participants acknowledged that they had
formal academic supports (n=31; 82%) in place through an Individualized Education Program
(IEP) or Section 504 Plan. Despite this, HRQOL scores as it pertains to the school setting were
impaired for a significant portion of respondents. Pediatric psychologists can support families in
advocating for additional accommodations and related services, provide psychoeducation about
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their legal rights, and assist them in connecting with school-based advocates or community
resources for tutoring. Additionally, efforts should be made to collaborate with patients’
educational teams, especially when patients experience notable changes in their health status or
unexpected hospitalizations.
The emotional subscale was the domain that led to the largest discrepancy between the
respondents, with parents perceiving their children as having more problems in this area.
Regardless, a significant portion of parents and patients endorsed scores below the clinical
threshold for emotional well-being. These findings highlight the importance of screening as a
mechanism to identify at-risk patients and provide necessary interventions. When formal
treatment is deemed necessary, evidence-based interventions that have been validated for
populations with chronic medical conditions are ideal. For example, ACT-based interventions
have demonstrated positive effects on adjustment, quality of life, life satisfaction, adherence
issues, and mood-related concerns among individuals with neuromuscular disorders (Ahlström &
Sjöden, 1996; Graham et al., 2015; Kratz et al., 2013). Traditional CBT approaches have also
been shown to be effective in managing distress, functional impairment, and mental health
symptoms associated with chronic medical conditions (Law et al., 2019; Thompson et al., 2011).
Not only did this study extend the existing research regarding the HRQOL of youth with
DMD from the perspectives of both patients and caregivers, but it sought to identify potentially
modifiable predictors that influence different HRQOL domains across respondents. Specifically,
this study identified family functioning as a factor associated with a number of HRQOL
outcomes (i.e., patient-reported physical HRQOL and parent-reported psychosocial HRQOL),
which is a concept that has been neglected in the research with youth with DMD. Clinically, the
formal assessment of family functioning using a measure intended for caregivers with children
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with chronic medical conditions has also been an area that has not been the focus of standard
clinical care for patients with DMD. Measures that better understand the impact of disease and
treatment on family functioning and parenting may be more specific and sensitive to capturing
the distinct problems that families’ experience with children with medical complexities (Geffken
et al., 2008), and subsequently lead to more tailored interventions that more adequately address
the needs of these families. Thus, family-level screenings and interventions focused on
alleviating parenting stress and improving family functioning in this population could have
significant effects not only on parents, but also for youth with DMD. Given the high level of
stress associated with caring for youth with DMD, parent support groups can be implemented to
address adjustment to illness and coping and enhance social connections. Problem-solving
therapy has also been shown to be an effective method of treatment for parents with children
with chronic diseases (Law et al., 2014).
Additionally, the boys’ experience of pain was found to be a contributing factor to childreported psychosocial HRQOL. It is reasonable to assume that frequent episodes of pain likely
lead to increased distress and interferes with one’s ability to participate in school and social
events, which aligns with the findings of this study. Thus, objective multidimensional assessment
and treatment of pain symptoms should be a standard part of clinical care and may aid in
improving HRQOL in youth with DMD. Implementing interventions to enhance youth’s ability
to manage and cope with pain should be a priority. Acceptance and commitment therapy (ACT)
and cognitive behavioral therapy (CBT) have been found to be efficacious for chronic pain
patients by addressing illness perceptions and pain-related interference in daily tasks and valued
activities (Palermo et al., 2010; Veehof et al., 2016). Additionally, integrating palliative care into
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the treatment of boys with DMD would be ideal, as such services can be valuable for pain
management and symptom relief (Janisch et al., 2020).
Age was also consistently identified as an indicator of HRQOL across nearly all domains.
The results suggest that although disease progression is associated with reduced physical
HRQOL, it may not be related to poorer psychosocial HRQOL, as older patients in this sample
endorsed better psychosocial outcomes. This finding is also supported by prior work, but it is
important to emphasize that longitudinal studies are needed to truly confirm this information.
Although age is not a modifiable factor, psychologists frequently provide psychoeducation-based
interventions to empower patients/families, relieve uncertainty, address misconceptions, and
promote adjustment to illness (Barlow & Ellard, 2006; Thompson & Young-Saleme, 2015).
Thus, learning that advancing age does not necessarily coincide with a progressive deterioration
in psychosocial well-being could serve as a source of comfort and hope for children and parents,
especially for those who are in the early stages of the disease or recently diagnosed. Similarly,
anticipatory guidance regarding the disease progression and planning and preparing for changes
in functioning across the disease stages are also critical in supporting patients and their families
with adjusting to the illness.
Limitations
Despite the various strengths that have been previously discussed, this study is not
without its limitations. The most pronounced and unexpected complication that arose during this
study was the global pandemic, which halted all non-essential research activities at the hospital
for over four months. Upon obtaining approval to resume the study with COVID-19 protocols in
place, there were added logistical challenges to conducting research in a hospital setting with a
medically complex population. There were restrictions on the number of patients and providers
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who could be present in clinic simultaneously. Efforts were also made to significantly reduce the
amount of time that patients and their families were spending in clinic and/or limiting the
number of contacts with providers by offering telehealth appointments when feasible and/or
eliminating their visits with providers for non-emergent needs. Thus, the principal investigator
was not allowed to be present in clinic and had to rely on members of the research team to
confirm eligibility, consent, and distribute the questionnaires. Due to the shortened appointments
and need to minimize contact, members of the research team were limited in their ability to assist
DMD participants in completing the questionnaires as needed and instead parents had to provide
support. This arrangement may have resulted in some parents inadvertently influencing their
child’s responses or resulted in some boys opting to answer questions differently than if a
research team member was helping them. Furthermore, cognitive and/or other
neuropsychological impairments of some of the participants may have interfered with their
ability to complete the measures and/or impacted the validity of the data obtained from the selfreport measures.
Beyond the hospital-wide protocols, it should not come as a surprise that there was an
increase in the number of appointments that were re-scheduled or cancelled, as families
expressed concerns about leaving their homes and going to the hospital with their medically
compromised loved ones. Consequently, data collection occurred across fewer months and the
anticipated sample size was not achieved. Despite the small sample size of this study (39
pediatric patients and 44 caregivers) power analyses demonstrated that the sample met the
suggested N. The sample size was also similar to other studies conducted with patients with
dystrophinopathies, with many clinic-based samples ranging anywhere from 24-65 participants.
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Additionally, the sample that was utilized was obtained via convenience sampling within
a single multidisciplinary clinic at a large pediatric hospital in Western United States, which may
limit the generalizability. It has been argued that given the severity of the disease, it is reasonable
to assume that almost all boys with DMD are managed at a tertiary-care clinic; thus, patients
recruited through such clinics are likely to be representative of the DMD population. However,
the shortened timeframe for data collection did not allow for the opportunity to connect with all
patients and their families with DMD, resulting in a sample that likely did not capture the
breadth and depth of diversity in terms of ethnicity, disease stage, parental marital status, income
level, and family composition. Similarly, 81% of caregivers identified as female, indicating that
the perspectives of male caregivers/fathers are largely missing from this study. Not only were
questionnaire ratings obtained from a single caregiver, but the cross-sectional nature of this study
only provided a snapshot of HRQOL and family impact at one time point. Common-method
variance also cannot be overlooked as a potential limitation, as the parent-reported models
integrated variables that were from a single reporter. This is important to consider in this
population as stress experienced by parents may bias their perception of their child’s functioning.
Furthermore, although this study incorporated multiple methods of assessment, it still
relied on self-reported questionnaires, which inherently runs of the risk of being biased. It is also
worth noting that there is no way of knowing just how much parent and child fears and worries
and activity restrictions related to COVID-19 impacted their responses on the measures of wellbeing and HRQOL. COVID-19 has had an impact on all of our lives, but individuals with
significant medical complexities and compromised immune systems, like those with DMD, and
their families have been even more restricted, with many children transitioning to remote
learning for the entirety of the school year and families limiting the time they spend outside the

80
home and dramatically reducing the number of direct interactions with people not residing in
their household. Consequently, it is reasonable to assume that living with special healthcare
needs in the midst of a pandemic may have led to poorer outcomes on rating scales than if this
study had occurred before the start of COVID-19.
Another potential limitation is the accuracy of patients’ medical charts. Patient medical
charts are supposed to be updated each time a patient visits the clinic and/or the hospital, but it is
reasonable to assume that these updates are not always made and information regarding medical,
psychiatric, and/or neurodevelopmental diagnoses may not be adequately documented in the
chart. However, many of the patients have undergone recent comprehensive neuropsychological
evaluations, which provides increased confidence in the accuracy of the psychiatric and
neurodevelopmental diagnoses outlined in their medical charts.
Future Directions
Given the exploratory nature of this study and the paucity of research related to this topic,
there are many areas to continue exploring within this medically complex population. Overall,
correlations were identified between many of the independent and dependent variables examined
in this study, but it is possible that the predictive relationships would have been stronger if a
larger sample size had been achieved. It would be important to replicate these findings with a
larger, more diverse sample, potentially via a national multi-site study. Also, the sample was
largely comprised of female caregivers; thus, greater attention should be given to recruiting male
caregivers/fathers in future studies to better understand their perception of their child’s HRQOL.
Although HRQOL ratings were obtained from both caregivers and patients, this study still relied
on self-report measures. The use of observational data and qualitative information may deepen
and enhance the understanding of predictors of HRQOL. Similarly, exploring differences in
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HRQOL ratings between female caregivers identified as being carriers of the DMD mutation and
mothers who are unaware of their carrier status and/or those who do not carry genetic variants
would be beneficial to explore. It may be possible that mothers with a carrier diagnosis who are
experiencing guilt and self-blame underestimate their child’s HRQOL and over report the
severity of their symptoms.
The cross-sectional nature of the study precluded an examination of the casual links
between the variables and HRQOL scores; thus, longitudinal research is needed to better
understand variations in these variables over the course of the disease, from diagnosis through to
end of life. Efforts should be made to evaluate other potentially modifiable psychosocial,
behavioral, and environmental predictors of HRQOL. Strong correlations were identified
between pain and several of the HRQOL scores, warranting further investigation with more
detailed methods of assessment rather than a single item. Future research also should consider
investigating the effects of illness perceptions and beliefs, patient and caregiver coping
strategies, symptoms of anxiety and depression, and/or peer relationships on HRQOL, which
have been identified as determinants of patient well-being among other pediatric populations
(Conway et al., 2016; Drakouli et al., 2015; Santos et al., 2016). This researcher had intended to
examine patient reported quality of family relationships as a predictor variable (i.e., the PatientReported Outcomes Measurement (PROMIS ®) Family Relationships questionnaire), but
unfortunately this measure had to be eliminated to reduce the amount of time that patients and
their families were spending in clinic visits. Thus, this would be another avenue worth exploring.
A greater understanding of factors that influence HRQOL should result in more interventionbased studies.
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Finally, given the predictive relationships between family functioning on child-reported
physical and/or psychosocial summary scores, further research is warranted to investigate how
neuromuscular clinics are identifying at-risk patients and families and addressing areas of
concern, as well as the ways in which they are evaluating the impact of targeted psychological
interventions on patient and family outcomes. More importantly, it will be critical to understand
which specific interventions and recommendations are associated with improvements in HRQOL
and family well-being.
Conclusion
The hallmark feature of DMD is degenerative muscle weakness and wasting, which
results in multisystem, life-threatening complications and secondary symptoms (e.g., pain, sleep
problems, gastrointestinal issues, and swallowing dysfunction), and ultimately, a shortened life
expectancy. The profound impairment in muscle function and multi-organ complications leads to
a gradual deterioration in functional abilities, restricted participation in age-related activities, and
increased dependence on caregivers (Bendixen et al., 2012; Mah et al., 2008; McDonald, 2002).
With no cure, treatment is largely focused on prolonging survival, limiting the degree of
impairment, and enhancing HRQOL (Birnkrant et al., 2018).
This study replicated previous work that youth with DMD present with low levels of
physical and psychosocial HRQOL from the perspectives of parents and caregivers. The social
aspects of HRQOL was identified as the most problematic area across both respondent groups.
More importantly, this study sought to expand the limited knowledge of modifiable psychosocial
factors affecting youth with DMD. The results indicated that age, pain, and/or family functioning
had a predictive influence on different domains of HRQOL. These findings underscore the
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importance of formally assessing pain and family functioning and providing therapeutic
interventions, which may potentially enhance HRQOL in patients with dystrophinopathies.
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Principal Investigator:
COMIRB No:
Version Date:
Study Title:

Noelle Whitney, MA/CAS
19-2552
02/05/2020

Health-Related Quality of Life and Psychosocial Factors in Youth with
Neuromuscular Disorders

You are being asked to be in a research study. This form provides you with information about the
study. A member of the research team will describe this study to you and answer all of your
questions. Please read the information below and ask questions about anything you don’t
understand before deciding whether or not to take part.
Why is this study being done?
This study plans to learn more about psychosocial factors, health-related quality of life,
demographic and medical information in youth and young adults with dystrophinopathies (i.e.,
Duchenne or Becker muscular dystrophy).
You are being asked to be in this research study because you are the parent/legal guardian of a
male between the ages of 5- and 25-years-old who has a formal diagnosis or suspected
diagnosis of a dystrophinopathy or you are a male between the ages of 5- and 25-years-old and
have a formal diagnosis or suspected diagnosis of a dystrophinopathy. Additionally, you are a
patient or parent/legal guardian who is being seen through the Children’s Hospital Colorado
(CHCO) Neuromuscular Clinic.
Other people in this study
Up to 80 people will participate in the study.
What happens if I join this study?
If you join the study, you will participate during one of your routine clinic visits with the
Children’s Hospital Colorado Neuromuscular Multidisciplinary Clinic. Your involvement in
this study will take approximately between 30-45 minutes. You will be asked to complete a
number of questionnaires about your thoughts, feelings, well-being, family life, and behavior.
Your parent will also be asked to fill out a form to obtain demographic/background information
and a questionnaire asking about their perspective of their youths’ thoughts, feelings, wellbeing, and behavior. Additionally, parents will complete a questionnaire about their own
thoughts, feelings, family life, and behavior.
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Given the researchers involvement in the Children’s Hospital Colorado Neuromuscular Clinic,
they will have access to your or your child’s medical chart to extract information about
medications and the presence of other diagnoses.
What are the possible discomforts or risks?
Discomforts you may experience while in this study include feelings of guilt or embarrassment
when thinking or reporting on their own behaviors or attitudes on the study measures. A
licensed clinical psychologist, Andrea Miele, Ph.D., will be available if uncomfortable feelings
arise that you wish to discuss.
You do not have to complete any questions that make you feel uncomfortable. You can choose
to stop participating in the study at any point for any reason.
There is the potential risk that patient information is accidentally seen by someone who is not
on the research protocol. We will do all that we can to protect your information, but it cannot
be guaranteed. Your information and all the data gathered through this study will be stored in
secure, encrypted, and password protected databases and servers. To further ensure
confidentiality, you will be assigned a randomly generated study ID. This ID will be used to
replace your name in all of your responses so that none of your responses will be linked to your
name.
What are the possible benefits of the study?
This study is designed for the researcher to learn more about youth with dystrophinopathies.
This study is not designed to treat any illness or to improve your health. Also, there may be
risks, as discussed in the section describing the possible discomforts or risks.
Will I be paid for being in the study?
You will not be paid to be in the study.
Will I have to pay for anything?
It will not cost you anything to be in the study.
Is my participation voluntary?
Taking part in this study is voluntary. You have the right to choose not to take part in this
study. If you choose to take part, you have the right to stop at any time. If you refuse or decide
to withdraw later, you will not lose any benefits or rights to which you are entitled.
Who do I call if I have questions?
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The researcher carrying out this study is Noelle Whitney, MA/CAS. You may ask any questions
you have now. If you have questions later, you may call Noelle at (720) 777-6214.
You may have questions about your rights as someone in this study. You can call Noelle
Whitney with questions. You can also call the Multiple Institutional Review Board (IRB). You
can call them at 303-724-1055.
Who will see my research information?
The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect
information about you. Federal and state laws including the Health Insurance Portability and
Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you
what information about you may be collected in this study and who might see or use it.
The institutions involved in this study include:
• University of Colorado Denver
• Children’s Hospital Colorado
• University of Northern Colorado
• Children’s Hospital Colorado shares a medical record system with the Barbara Davis
Center and PedsConnect; therefore, it is also possible that your information could be
viewed by healthcare professionals at these organizations.
We cannot do this study without your permission to see, use, and give out your information.
You do not have to give us this permission. If you do not, then you may not join this study.
We will see, use and disclose your information only as described in this form and in our Notice
of Privacy Practices; however, people outside the University and its affiliate health systems
may not be covered by this promise.
We will do everything we can to keep your records a secret. It cannot be guaranteed.
The use and disclosure of your information has no time limit. You can cancel your permission
to use and disclose your information at any time by writing to the study’s Primary Investigator,
at the name and address listed below. If you do cancel your permission to use and disclose your
information, your part in this study will end and no further information about you will be
collected. Your cancellation would not affect information already collected in this study.
Noelle Whitney, MA/CAS
Children’s Hospital Colorado
13123 East 16th Avenue
Aurora, CO 80045
Both the research records that identify you and the consent form signed by you may be looked at
by others who have a legal right to see that information, such as:
§

Federal offices such as the Food and Drug Administration (FDA) that protect research
subjects like you
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§

People at the Colorado Multiple Institutional Review Board (COMIRB)

§

The study doctor and the rest of the study team

§

Officials at the institution where the research is being conducted and officials at other
institutions involved in this study who are in charge of making sure that we follow all of
the rules for research

We might talk about this research study at meetings. We might also print the results of this research
study in relevant journals. But we will always keep the names of the research subjects, like you,
private.
Some things we cannot keep private. If you give us any information about child abuse or neglect
we have to report that to Colorado Department of Human Services. Also, if we get a court order
to turn over your study records, we will have to do that.
Some things we cannot keep private: If you tell us you are going to physically hurt yourself or
someone else, we have to report that to the Colorado Department of Human Services. Also, if we
get a court order to turn over your study records, we will have to do that.
You have the right to request access to your personal health information from the Investigator.
What happens to Data that are collected in this study?
Scientists at the University and the health systems involved in this study work to find the causes
and cures of disease. The data collected from you during this study are important to this study
and to future research. If you join this study:
• The data are given by you to the investigators for this research and so no longer belong
to you.
• Both the investigators and any sponsor of this research may study your data collected
from you.
• If the data are in a form that identifies you, the University or the health systems
involved in this study may use them for future research only with your consent or IRB
approval.
• Any product or idea created by the researchers working on this study will not belong
to you.
• There is no plan for you to receive any financial benefit from the creation, use or sale
of such a product or idea.

132
Agreement to be in this study and use my data
I have read this paper about the study or it was read to me. I understand the possible risks and
benefits of this study. I understand and authorize the access, use and disclosure of my information
as stated in this form. I know that being in this study is voluntary. I choose to be in this study: I
will get a signed and dated copy of this consent form.
Signature:

Date:

Print Name:

Consent form explained by:

Date:

Print Name:

Signature of Witness:

Date:

Print Name:
Witness of Signature
Witness of consent process
___________________________________________
Child (13-17 year olds)
Consent form explained by:_____________________
Print Name:__________________________________

Date_________

Date:________
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Person in Charge of the Study: Noelle Whitney
COMIRB No: 19-2552
Version Date: 02/05/2020
Assent Form for: Health-Related Quality of Life and Psychosocial Factors in Youth with
Neuromuscular Disorders
What is this study about?
You are being asked if you want to be in this research study. The goal of this study is to learn more
about you, your health, and your family.
Why are you asking me?
You are being asked to be in the study because you are male, between the ages of 5- and 25-yearsold and have a formal diagnosis or suspected diagnosis of Duchenne muscular dystrophy or
another dystrophinopathy (i.e., Duchenne or Becker muscular dystrophy).
What Do I Have to Do or What Will Happen to Me?
If you are in the study, you will be asked to independently complete several questionnaires
regarding your thoughts, feelings, behaviors, physical functioning, and family life during your
routine visit to the Children’s Hospital Colorado Neuromuscular Multidisciplinary Clinic. These
questionnaires will take you approximately 30 to 45 minutes to complete.
You don’t have to answer any questions that you don’t want to, and you can stop at any time.
Will this Hurt?
There are no medical procedures involved with this research study.
Can I ask Questions?
You can ask any questions that you have now about the study.
If you have a question later, you can ask and get an answer. If you want to, you can call Noelle
Whitney, principal investigator, at (720) 777-6214 or Andrea Miele, co-investigator, at (720)
777-5513.
Do I Have to Do This?
You do not have to be in this study. No one will be mad at you if you say, “no.” You can choose
to stop at any time. Just tell the researcher if you want to stop.
Do you want to be in the study at this time? (Check one box)
o Yes o No
You will get a copy of this form to keep.
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Child’s Signature:

Date:

Child’s Printed Name:

_____

Consent form explained by:

_____________________
(Print name)

I have explained the research at a level that is understandable by the child and believe that the
child understands what is expected during this study.
Signature of Person Obtaining Assent: _________________________________
Date: ____________
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DEMOGRAPHIC QUESTIONNAIRE
ID#:_________
Today’s Date: ______________
Who is completing this form?
Mother, Stepmother, or Foster mother
Father, Stepfather, or Foster father

Guardian (please specify): ____________
Other: _____________________________

INFORMATION ABOUT YOUR CHILD
Age: ________

Gender: _________________

Grade: _______

Preferred Language: ______________________
Race/Ethnicity (Check all that apply):
Asian/Pacific Islander
Black or African American
Hispanic or Latino
Native American or American Indian
White, Non-Hispanic
Other (Please specify): ______________
Age of diagnosis of neuromuscular disorder: __________
Ambulation status:
Walking without the use of orthotic devices (e.g., braces) or mobility aids (e.g., cane, walker)
Walking with the use of orthotic devices (e.g., braces) or mobility aids (e.g., cane, walker)
Intermittent wheelchair use
Full-time wheelchair use
In the past 12 months, has your child had any overnight hospital visits for issues related to their
neuromuscular disorder? No Yes
If yes, how many times? ________
In the past 12 months, has your child been seen in an emergency department for issues related to
their neuromuscular disorder? No Yes
If yes, how many times? ________
Is your child currently receiving formal supports and services in school for their academic,
physical, and/or medical needs via an Individualized Education Program (IEP)?
No
Yes
I don’t know
Not applicable
Is your child currently receiving formal supports and services in school for academic, physical,
and/or medical needs via a Section 504 Plan?
No
Yes
I don’t know
Not applicable
INFORMATION ABOUT PARENT/GUARDIAN
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Age: ________

Gender: _________________

Preferred Language: ______________________
Race/Ethnicity (Check all that apply):
Asian/Pacific Islander
Black or African American
Hispanic or Latino
Native American or American Indian
White, Non-Hispanic
Other (Please specify): ___________________
Relationship Status:

Single
Divorced

Living with someone
Separated

Married
Widowed

What is the highest degree or level of school you completed? (If you are currently enrolled in
school, please indicate the highest degree you have received).
5th grade or less
6th-8th grade
9th-12th grade
High school graduate
Some college or certification course
Associate degree
Trade/Technical/Vocational Training
Bachelor’s degree
Graduate or professional degree
Other, please specify: ____________________
What is your family’s estimated yearly income (from all sources and before taxes)?
Less than $20,000
$20,000 to $34,999
$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
Over $100,000
What is your current work status?
Employed full-time (Over 35 hours/week) outside the home
Employed part-time (Less than 35 hours/week) outside the home
Unemployed and currently looking for work
Unemployed and not currently looking for work
Student
Retired
Active military
Self-employed
Disabled; unable to work

Homemaker

How would you describe your household? Please choose only one of the following:
Two-parent household
One-parent household
Step-parent household
Other, please specify: _________________
Have you or anyone in your immediate family completed genetic carrier testing?
No
Yes
If yes, who (please specify): ____________________
What were the results of the testing?
Positive for a mutation in the DMD gene
Negative for a mutation in the
DMD gene
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Have you been diagnosed by a medical or mental health professional with a psychiatric condition
(e.g., anxiety, depression, bipolar disorder)? No
Yes
If yes, what is your diagnosis? _________________________________________
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User agreement
Special Terms
Mapi Research Trust, a non-for-profit organisation subject to the terms of the French law of 1st July 1901, registered in
Carpentras under number 453 979 346, whose business address is 27 rue de la Villette, 69003 Lyon, France, hereafter referred
to as “MRT” and the User, as defined herein, (each referred to singularly as a “Party” and/or collectively as the “Parties”), do
hereby agree to the following User Agreement Special and General Terms:
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
Recitals
The User acknowledges that it is subject to these Special Terms and to the General Terms of the Agreement, which are included
in Appendix 1 to these Special Terms and fully incorporated herein by reference. Under the Agreement, the Questionnaire
referenced herein is licensed, not sold, to the User by MRT for use only in accordance with the terms and conditions defined
herein. MRT reserves all rights not expressly granted to the User.
The Parties, in these Special Terms, intend to detail the special conditions of their partnership.
The Parties intend that all capitalized terms in the Special Terms have the same definitions as those given in article 1 of the
General Terms included in Appendix 1.
In this respect, the Parties have agreed as follows:

Article 1. Conditions Specific to the User
Section 1.01

Identification of the User

User Name

Noelle Whitney

Legal Form

Student

Address

501 20th Street
80639 Greeley

Country

United States of America

Email address

noelle.whitney@unco.edu

Section 1.02

Identification of the Questionnaire

Title

Pediatric Quality of Life Inventory™ (PedsQL™)

Author(s)

Varni JW
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